Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary  and Confidential Page 1  
 
 
PROTOCOL  
  
TITLE: A Multicenter Open-Label Phase 1b/[ADDRESS_843411] Disease  
PROTOCOL NUMBER: PCYC-1129-CA  
STUDY DRUG: Ibrutinib (PCI-[ZIP_CODE]) 
IND NUMBER: 102,688 
SPONSOR MEDICAL MONITOR: Lori Styles MD Pharmacyclics, LLC Phone: +[PHONE_13146] Email: [EMAIL_12061] 
SPONSOR: Pharmacyclics LLC  [ADDRESS_843412]  Sunnyvale, CA [ZIP_CODE] [LOCATION_002] of America 
 Pharmacyclics' protocol deve loped in collaboration with:  
 David B. Miklos, MD PhD Stanford University Stanford, CA [ZIP_CODE] Samantha Jaglowski, MD MPH Ohio State University Columbus, OH [ZIP_CODE] 
DATE FINAL: 
Original: Amendment 1: Amendment 2:  [ADDRESS_843413]/ethics 
committee. This information cannot be used for any other purpose other than the evaluation or 
conduct of the clinical study without the pr ior written consent of Pharmacyclics LLC 
  

Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843414] Disease .................................................... 18 
1.3.  B Cells and the Development of cGVHD ..................................................................... 18 
1.4.  Other Lymphocytes and the Development of cGVHD ................................................. 19 
1.5.  Current Therapi[INVESTIGATOR_631933] ...................................................................................... 19 
1.6.  Ibrutinib Overview ........................................................................................................ 20 
1.7.  Summary of Nonclinical Data ....................................................................................... 21 
1.7.1.  Pharmacology ................................................................................................................ 21 
1.7.2.  Toxicology .................................................................................................................... 21 
[IP_ADDRESS]. Carcinogenesis, Mutagenesis, Impairment of Fertility ................................................. [ADDRESS_843415] Metabolism .................................................................. 22 
1.8.2.  Summary of Clinical Safety ..........................................................................................23  
[IP_ADDRESS]. Monotherapy Studies ....................................................................................................23  
1.8.3.  Risks ......................................................................................................................... .....24 
[IP_ADDRESS]. Bleeding Related Events ...............................................................................................24  
[IP_ADDRESS]. Cytopenia ..................................................................................................................... .24 
[IP_ADDRESS]. Atrial Fibrillation ..........................................................................................................24  
[IP_ADDRESS]. Diarrhea ...................................................................................................................... ...24 
[IP_ADDRESS]. Infections .................................................................................................................... ...24 
[IP_ADDRESS]. Second primary Malignancies .......................................................................................24  
[IP_ADDRESS]. Rash ...............................................................................................................................25  
1.9.  Study Rationale .............................................................................................................25  
1.9.1.  Ibrutinib (Btk Inhibitor) Targets of Interest in cGVHD ................................................ 25 
1.9.2.  Ibrutinib in Murine cGVHD Models............................................................................. 25 
1.9.3.  Justification of Study Design and Dose Rationale ........................................................ 26 
2.  STUDY OBJECTIVE .................................................................................................26  
2.1.  Primary Objective .........................................................................................................26  
2.2.  Secondary Objectives .................................................................................................... 27 
2.3.  Exploratory Objective(s) ...............................................................................................27  
3.  STUDY DESIGN .........................................................................................................28  
3.1.  Overview of Study Design ............................................................................................28  
3.2.  Study Schema ................................................................................................................29  
3.3.  Phase 1b Safety/DLT Assessment ................................................................................[ADDRESS_843416] SELECTION ............................................................................................ 30 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary  and Confidential Page 4 4.1.  Inclusion Criteria ...........................................................................................................30  
4.2.  Exclusion Criteria..........................................................................................................32  
5.  TREATMENT OF SUBJECTS .................................................................................34  
5.1.  Treatment Allocation and Blinding ............................................................................... 34 
5.2.  Study Treatment ............................................................................................................34  
5.2.1.  Phase 1b Dose Selection and Stoppi[INVESTIGATOR_1869] ............................................................... 34 
5.2.2.  Definition of Dose Limiting Toxicities .........................................................................35  
5.2.3.  Phase 2 ..........................................................................................................................35  
5.3.  Study Medication ..........................................................................................................35  
5.3.1.  Ibrutinib .........................................................................................................................35  
[IP_ADDRESS]. Formulation/Packaging/Storage .................................................................................... 35 
[IP_ADDRESS]. Dose and Administration .............................................................................................. 36 
[IP_ADDRESS]. Overdose ...................................................................................................................... .36 
[IP_ADDRESS]. Dose Modification for Adverse Reactions .................................................................... 36 
[IP_ADDRESS]. Dose Modification for Hepatic Impaired Subjects........................................................ 37 
5.3.2.  Management of Immunosuppression ............................................................................38  
5.3.3.  Management of Steroids ............................................................................................... 38 
5.3.4.  Prophylaxis for Infections ............................................................................................. 38 
6.  CONCOMITANT MEDICATIONS/PROCEDURES .............................................38  
6.1.  Concomitant Medications ............................................................................................. 38 
6.1.1.  Permitted Concomitant Medications ............................................................................. 38 
6.2.  Medications to be Used with Caution ........................................................................... 39 
6.2.1.  CYP3A Inhibitors/Inducers ........................................................................................... [ADDRESS_843417] Their Plasma C oncentrations Altered by [CONTACT_183939] .................. 39 
6.2.3.  QT Prolonging Agents ..................................................................................................39  
6.2.4.  Antiplatelet Agents and Anticoagulants ........................................................................ 40 
6.3.  Prohibited Concomitant Medications ............................................................................ 40 
6.4.  Guidelines for Ibrutinib Management  with Surgeries or Procedures ............................40  
6.4.1.  Minor Surgical Procedures ............................................................................................40  
6.4.2.  Major Surgical Procedures ............................................................................................40  
6.4.3.  Emergency Procedures .................................................................................................. 41 
7.  STUDY EVALUATIONS ...........................................................................................41  
7.1.  Description of Procedures ............................................................................................. 41 
7.1.1.  Screening/Administrative .............................................................................................. 41 
7.1.2.  Informed Consent .......................................................................................................... 41 
7.1.3.  Confirm Eligibility ........................................................................................................41  
7.1.4.  Medical History and Demographics..............................................................................41  
7.1.5.  Prior and Concomitant Medications ............................................................................. 42 
7.1.6.  Adverse Events ............................................................................................................. 42 
7.1.7.  Physical Examination .................................................................................................... 42 
7.1.8.  Imaging ....................................................................................................................... ..42 
7.1.9.  Karnosky Performance Status ....................................................................................... 42 
7.1.10. Vital Signs .....................................................................................................................42  
7.1.11. Laboratory .................................................................................................................... .43 
[IP_ADDRESS].  Hematology ................................................................................................................... 43 
[IP_ADDRESS].  Chemistry (Serum) ........................................................................................................43  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary  and Confidential Page 5 [IP_ADDRESS].  Coagulation Studies ......................................................................................................43  
[IP_ADDRESS].  Hepatitis Serologies ......................................................................................................43  
[IP_ADDRESS].  Donor/Host Chimerism ................................................................................................. 43 
[IP_ADDRESS].  Immunosuppressant Level ............................................................................................43  
[IP_ADDRESS].  Pregnancy Test ..............................................................................................................43  
[IP_ADDRESS].  Quantitative Serum Immunoglobulins .......................................................................... 44 
7.1.12. Diagnostics/Procedures ................................................................................................. 44 
[IP_ADDRESS].  ECG ...............................................................................................................................44  
[IP_ADDRESS].  Oxygen Saturation/Pulmonary Function Tests (PFTs) .................................................44  
7.1.13. Pharmacokinetics/Biomarkers ...................................................................................... 44 
[IP_ADDRESS].  Pharmacokinetics .......................................................................................................... 44 
[IP_ADDRESS].  Biomarkers and Pharmacodynamic (PD) Studies .........................................................45  
[IP_ADDRESS].  T/B/NK Counts ............................................................................................................. 46 
7.2.  Efficacy Evaluations .....................................................................................................47  
7.2.1.  NIH Response Criteria (see A ppendix F and Appendix G) .......................................... [ADDRESS_843418] Information ....................................................................................................... 55 
10.2.  Endpoints ..................................................................................................................... .55 
10.2.1. Primary Endpoints .........................................................................................................55  
10.2.2. Secondary Efficacy Endpoints ......................................................................................56  
[IP_ADDRESS].  Rate of Sustained Response for at Least 5 Months ....................................................... 56 
[IP_ADDRESS].  Duration of Response (DOR) ........................................................................................56  
[IP_ADDRESS].  Corticosteroid Requirement Changes Over Time ......................................................... 56 
[IP_ADDRESS].  Change in cGVHD Symptom Scale ..............................................................................56  
10.2.3. Safety Endpoints ...........................................................................................................56  
10.2.4. Exploratory Endpoints .................................................................................................. 56 
[IP_ADDRESS].  Photographic Changes in Skin and Mucocutaneous Manifestations. ........................... 56 
[IP_ADDRESS].  Pharmacokinetic Analysis .............................................................................................57  
[IP_ADDRESS].  Biomarker and Pharmacodynamic Studies ................................................................... 57 
[IP_ADDRESS].  Failure Free Survival ..................................................................................................... 57 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary  and Confidential Page 6 10.3.  Sample Size Determination ........................................................................................... 57 
10.4.  Efficacy Analysis ..........................................................................................................57  
10.5.  Safety Analysis .............................................................................................................58  
11.  ADVERSE EVENT REPORTING ............................................................................ 59 
11.1.  Definitions .....................................................................................................................59  
11.1.1. Adverse Events ............................................................................................................. 59 
11.1.2. Serious Adverse Events.................................................................................................60  
11.1.3. Severity Criteria (Grade 1-5) ........................................................................................61  
11.1.4. Causality (Attribution) .................................................................................................. [ADDRESS_843419] (AESI) ................................................................... 64 
[IP_ADDRESS].  Major Hemorrhage ........................................................................................................[ADDRESS_843420] (IRB), Resear ch Ethics Board (REB) and Independent 
Ethics Committee (IEC) Approval ................................................................................[ADDRESS_843421] Maintenance ............................................................... 68 
12.8.  Investigational Study Drug Accountability ...................................................................68  
12.9.  Study Monitoring/Audit Requirements ......................................................................... 69 
12.10. Investigator Responsibilities ......................................................................................... 70 
12.11. Sponsor Responsibilities ...............................................................................................70  
12.12. Financial Disclosure ......................................................................................................70  
12.13. Liability and Clinical  Trial Insurance ........................................................................... 70 
12.14. Protocol Amendments ...................................................................................................71  
12.15. Publication of Study Results .........................................................................................71  
12.16. Study Discontinuation ................................................................................................... 72 
13.  REFERENCES ............................................................................................................ 73 
14.  APPENDICES ............................................................................................................. 78 
 
  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843422] OF IN-TEXT TABLES  
Table 1: Ibrutinib Dose Modifications .......................................................................................37  
Table 2: Pharmacokinetic Sampling Schedule .......................................................................... 45 
Table 3: PD (BTK and ITK Occupancy) Sampli ng Schedule (collection for PCYC) .............. 46 
Table 4: T/B/NK Sampling Schedule (collection for PCYC).................................................... [ADDRESS_843423] OF APPENDICES 
Appendix A.  Schedule of Assessments ..................................................................................... 79 
Appendix B.  NIH Defined Diagnostic or Distinc tive Features of Chronic GVHD .................. 81 
Appendix C.  Karnofsky Performance Status Scores .................................................................83  
Appendix D.  Non-Investigational Treatments for cGVHD ....................................................... 84 
Appendix E.  Lee cGVHD Symptom Scale ...............................................................................85  
Appendix F.  Chronic GVHD Activity Assessment – Clinician ................................................87  
Appendix G.  Chronic GVHD Activity Assessment − Patient Self Report ................................ 92 
Appendix H.  Response Criteria for Partial Response and Progression in cGVHD ................... 93 
Appendix I.  Guidelines for Chronic GVHD Activity Assessment – Clinician (FORM A) ..... 95 
Appendix J.  Inhibitors and Inducers of CYP3A ....................................................................... 96 
Appendix K.  Child-Pugh Score ................................................................................................. 97 
 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary  and Confidential Page 8 SYNOPSIS 
Study Title: A Multicenter Open-label Phase 1b/[ADDRESS_843424] Disease 
Protocol Number: PCYC-1129-CA  
Study Phase: 1b/2 
Study Duration: Estimated to be 2-[ADDRESS_843425] 
and Reference Therapy: Ibrutinib will be supplied as [ADDRESS_843426] gelatin capsules for oral (PO) administration.
 
Objectives: Phase 1b: 
Primary Objective: 
• To evaluate the safety and tolerability of ibrutinib in steroid dependent/refractory chronic graft versus host disease (cGVHD) 
Secondary Objectives: 
• To evaluate the clinical efficacy of ibrutinib in steroid 
dependent/refractory cGVHD by [CONTACT_35755]: 
o Best overall cGVHD response (NIH-defined complete response [CR] and partial response [PR] ) 
o Rate of sustained response for at least 5 months 
o Duration of response (DOR) 
o Corticosteroid requirement changes over time 
o Change in symptom burden measured by [CONTACT_631951] 2:  
Primary Objective: 
• To evaluate the clinical efficacy of ibrutinib in steroid 
dependent/refractory cGVHD by [CONTACT_631952] (NIH-defined CR and PR) 
Secondary Objectives: 
• Rate of sustained response for at least 5 months 
• Duration of response (DOR) 
• To evaluate the safety and tolerability of ibrutinib in steroid 
dependent/refractory cGVHD 
• To evaluate the impact of ibrutinib on corticosteroid requirement 
changes over time 
• To evaluate ibrutinib treatment effect on change in symptom burden measured by [CONTACT_631953] (Phase 1b and Phase 2): 
• To evaluate the clinical efficacy of  ibrutinib by [CONTACT_631954] (FFS) at 6 and 12 months 
• To evaluate photographic changes in skin and mucocutaneous 
manifestations with ibrutinib treatment 
• To determine the pharmacokinetics (PK) of ibrutinib in subjects with cGVHD 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary  and Confidential Page 9 • To determine the alloreactive B cell depletion, T-helper cell 
composition, and BTK/ITK blockade including: 
o HY antigen-specific allogeneic B cell depletion in males who receive allo-HCT from a female donor. 
o Quantification of HY IgG and IgM alloreactive antibodies in males who receive allo-HCT from a female donor. 
o BTK and ITK binding site occupation. 
o B cell depletion, flow cytometric analysis of T-helper cell 
composition, T and B cell cytokine analysis, and phosphoflow analysis of CD4+ T-cell ITK blockade. 
 
Study Design: This is a Phase 1b/2 open-label study designed to evaluate the safety and 
efficacy of ibrutinib in treating subjects with steroid dependent/refractory 
chronic GVHD. 
Phase 1b will begin with the evaluation of the safety of standard dose 
(420 mg) ibrutinib with the potential for subsequent dose reductions if 
dose limiting toxicities (DLTs) are detected. A modified 3+3+[ADDRESS_843427] to Phase 2 of the study (recommended Phase 2 dose [RP2D], see Section 3.3.1). Between 
6-27 subjects will be evaluated in Phase 1b depending on the freque ncy
 of 
DLTs and need for dose reductions. 
Phase 2 will evaluate the efficacy of th e RP2D of ibrutinib determined in 
Phase 1b. Subjects will be given ibru tinib continuously along with their 
pre-existing immunosuppressants for cGVHD and followed for signs of 
progression/resolution of cGVHD. Approximately 34 subjects will be 
enrolled in Phase 2 to reach approximately 40 subjects (Phase 1b + Phase 
2 subjects) treated at the RP2D.  
Subjects not experiencing a DLT in the Phase 1b portion of the study are 
permitted to continue undergoing Phase 2 procedures and follow up at 
their Phase 1 dose. 
Population: Steroid dependent or refractory chronic graft versus host disease.  
Centers: Multiple, US  
Key Inclusion Criteria: 
Refer to Section [ADDRESS_843428] of 
inclusion/exclusion criteria. 1. Steroid dependent/refractory classic chro
nic GVHD defined at any 
time post-HCT as: 
a) Dependent disease - Persistent cGVHD manifestations requiring a 
glucocorticoid dose ≥ prednisone 0.25 mg/kg/day (0.5 mg/kg 
orally every other day or equivalent) for at least 12 weeks. 
b) Refractory disease - Progressive cGVHD manifestations despi[INVESTIGATOR_12847] a glucocorticoid dose ≥ prednisone 0.5 mg/kg/day 
(1 mg/kg orally every other day or equivalent) for at least [ADDRESS_843429] received pr e-transplant ibrutinib for other 
reasons besides cGVHD such as for the treatment of leukemia or lymphoma.  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843430] 56 days before starting ibrutinib. 
5. Chronic GVHD manifestations ( Appendix B ) that can be followed on 
phys
ical or laboratory exam including at least one of the following 
criteria:  
• >25% body surface area (BSA) NIH-defined criteria 
“Erythematous rash”  
• >4 total mouth score by [CONTACT_4289]-defined criteria  
6. Clinically stable or worsening cGVHD between Screening and Day 1 cGVHD response assessments (see Section 7.1.3) 
7. ≥18 y
ears of age 
8. Life expectancy ≥ 6 months 
9. Karnofsky performance status ≥60 (see Appendix C ) 
10. Adequate hepatic and rena l function as d e
fined as: 
a) Serum creatinine ≤ 1.[ADDRESS_843431] 
b) AST, ALT and Alkaline phosphatase ≤[ADDRESS_843432] or of non-hepatic 
origin, such as hemolysis 
c) Total bilirubin ≤[ADDRESS_843433] (unless bilirubin rise is due to Gilbert’s 
syndrome) 
d) Estimated Creatinine Clearance ≥30 mL/min (Cockcroft-Gault 
formula) 
11. Adequate hematological function defined as: 
a) Absolute neutrophil count ≥1.0 x 109/L and off growth factor 
support for 7 days 
b) Platelets ≥30 x 109/L and no transfusion support for 7 days 
c) Hemoglobin ≥8 g/dL and no transfusion or growth support for 
7 days 
12. PT/INR <1.[ADDRESS_843434] and PTT (aPTT) <1.[ADDRESS_843435] (unless 
abnormalities are unrelated to coagulopathy or bleeding disorder). 
13. ≤6 stools per day 
14. Oxygen saturation after exertion maintained at ≥88% on room air. If 
not, FEV1 ≥50% on pulmonary function tests performed within 
6 months of study entry.  
15. Ability to understand and willingness to sign a written informed 
consent form.  
16. Myeloablative or non-myeloablative allogeneic hematopoietic cell transplant for underlying hematological disease. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 11 Exclusion Criteria: Subjects are excluded if any of the following criteria are met: 
1. Known or suspected active acute GVHD. 
2. Received any investigational agents ≤28 days before starting 
ibrutinib. 
3. Current treatment with sirolimus AND either cyclosporine or 
tacrolimus. 
4. History of treatment with a tyrosine kinase inhibitor (eg, imatinib), 
purine analogs or other cancer chemotherapy in the 4 weeks prior to 
starting ibrutinib. 
5. Currently active, clinically signi ficant cardiovascular disease, such as 
uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as 
defined by [CONTACT_14174]; or a history of myocardial infarction, unstable angina, 
or acute coronary syndrome within 6 months prior to randomization. 
6. Any uncontrolled active systemic infection or infection requiring 
systemic treatment that was completed ≤[ADDRESS_843436]-transplant 
lymphoproliferative disease.  
8. History of other malignancy (not including the underlying 
malignancy that was the indication for transplant), with the following exceptions: 
• Malignancy treated with curative intent and with no evidence of 
active disease present for more than  3 years prior to Screening 
and felt to be at low risk for recurrence by [CONTACT_35425]; 
• Adequately treated nonmelanomatous skin cancer or lentigo maligna melanoma without current evidence of disease; 
• Adequately treated cervical carcinoma in situ without current evidence of disease. 
9. Subject is pregnant, breast-feeding, or of childbearing potential without a negative serum or urine pregnancy test within [ADDRESS_843437] not willing to comply with treatment or response evaluation. 
11. Moderate or severe hepatic impairment (Child-Pugh classification). 
12. Subject has a concurrent illness which in the opi[INVESTIGATOR_631934]. 
13. Concomitant use of warfarin or other Vitamin K antagonists  
14. Subject has a known allergy or hypersensitivity to ibrutinib. 
15. Vaccinated with live, attenuated v accines within [ADDRESS_843438] dose 
of ibrutinib. 
16. Known bleeding disorders (eg, von Willebrand’s disease or 
hemophilia). 
17. History of stroke or intracranial hemorrhage within 6 months prior to 
enrollment. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 12 18. Known history of human immunodeficiency virus (HIV) or active 
with hepatitis C virus (HCV) or hepatitis B virus (HBV). Subjects who are positive for hepatitis B co re antibody, hepatitis B surface 
antigen, or hepatitis C antibody must have a negative polymerase chain reaction (PCR) result before enrollment. Those who are PCR 
positive will be excluded. 
19. Major surgery within [ADDRESS_843439] dose of study drug. 
20. Concurrent use of a strong cytochrome P450(CYP) 3A inhibitor 
(Appendix I ) 
21. Unable to swallow capsules or malabsorption s yndro
me, disease 
significantly affecting gastrointestin al function, or resection of the 
stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or  complete bowel obstruction. 
Study Treatment: Ibrutinib will be dosed daily and will continue as long as the subject is 
deriving clinical benefit and the subj ect is not experiencing unacceptable 
toxicity.  
Phase 1b:  
Three dose levels of ibrutinib may be tested: 140 mg/day, 280 mg/day and 
420 mg/day. The starting dose will be 420 mg/day and the dose will be 
modified based on the occurrence of dose limiting toxicities (DLTs). 
Phase 1b will follow a modified 3+3+[ADDRESS_843440] 28 days of  study treatment is <33%. Before 
determining the RP2D, [ADDRESS_843441] completed the DLT observation period which is defined as 28 days of 
therapy. Using the modified 3+3+3 design, the maximum tolerated dose (MTD) is exceeded when ≥3 out of 9 subjects in a dose level experience a 
DLT. If there are 3 DLTs at a dose level, the MTD is exceeded and the next lower dose level will be enrolled.  
Enrollment in a dose level cohort will proceed as follows: 
• If no DLT is observed during the DLT observation period in the 
initial 3 subjects of a dose level,  then a second group of 3 subjects 
will be enrolled at the same dose level for a total of 6 subjects. If 0-1 DLT occur out of 6 subjects, then this dose will be the RP2D. If 2 DLTs occur out of 6, then the dose level cohort will be expanded to enroll a total of 9 subjects. If no further DLTs occur then this dose will be the RP2D. 
• If [ADDRESS_843442] 6 subjects. If no further DLT(s) are observed, then this dose will be the RP2D. If 2 DLTs are observed out of 6 subjects, then the dose level cohort will be expanded to enroll a total of 9 subjects. If no further DLTs are observed in this group 
of subjects then this dose will be the RP2D. 
• If 2 DLTs are observed in the initial 3 subjects, then enrollment to 
this dose level will be stopped. A DLT review will occur to determine if the dose should be lowered. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 13 • If [ADDRESS_843443] will discontinue treatment and not be replaced in that dose level. 
The decision to proceed with a RP2D or to dose reduce will be made in a 
Dose Level Review Meeting by [CONTACT_631955]. 
A dose limiting toxicity (DLT) is defined as any drug-related hematologic 
or non-hematologic toxicity Grade 3 or higher, with the following 
exceptions: 
• Grade 4 nausea, vomiting, or diarrhea or Grade 3 diarrhea defined 
by ≥7 stools/day persisting for [ADDRESS_843444] supportive care 
• Grade 4 neutropenia or Grade 3 neutropenia persisting for 14 days or Grade 3 neutropenia of any duration with fever 
• For subjects with Grade 2 rash at entry, DLT will be progression to Grade 3 AND a doubling of % BSA involvement 
• For subjects with Grade 3 rash at entry, DLT will be progression to Grade 4 OR a doubling of % BSA involvement 
Phase 2:
 
Following the establishment of the RP2D, the Phase 2 portion of the study will begin accruing additional subj ects. Approximately 40 subjects 
(cumulative from both Phase 1b and Phase 2) will be treated with the 
RP2D.  
Concomitant Therapy: Refer to Section 6 for infor mation on concomitant therapy. 
Safety Plan: This study will be monitored in accordance with the Sponsor’s 
Pharmacovigilance Committee procedures. Adverse events (AEs) and 
serious adverse events (SAEs) will be reviewed by [CONTACT_631956].  
Statistical Methods and Data Analysis: Phase 1:
 
Designed to determine the RP2D and toxicity profile of ibrutinib using the modified 3+3+3 design. Up to 3 dose levels will be explored. In 
observing ≤2 DLTs in 9 subjects, RP2D is determined.  
The Phase 1b efficacy data for subjects with RP2D will be combined with 
Phase 2 efficacy data. 
Phase 2
 
Primary Efficacy Analysis:  
Best overall cGVHD response rate is defined as the proportion of subjects 
who achieve a NIH-defined complete response (CR) or partial response 
(PR) during the study over all subjects who got RP2D from either Phase 1b portion or Phase 2 portion. The cGVHD response rate along 
with its 95% exact binomial confidence interval will be presented.  
Secondary Efficacy Analyses:
 
Secondary efficacy variables including sustained response rate, DOR, 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 14 corticosteroid requirement changes over time, and change in symptom 
burden as measured by [CONTACT_631957]. 
Efficacy analyses will be performed on all subjects who are enrolled for 
RP2D from either Phase 1b portion or Phase 2 portion.  
Safety Analysis:  
All subjects are to be monitored for adverse events during the study. 
Other safety measurements include clinical laboratory tests and vital signs. Descriptive statistics will be use to summarize safety data (adverse 
events [AEs], clinical laboratory tests and vital signs) for all subjects 
receiving ibrutinib. Summary statistics will include means, standard deviations, and medians for continuous variables and proportions for 
categorical variables. 
Interim Analysis Not applicable. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843445] aspartate aminotransferase 
AUC area under the curve 
BAFF B cell activating factor 
BCR B-cell receptor 
BSA body surface area 
Btk Bruton’s tyrosine kinase 
CFR US Code of Federal Regulations 
cGVHD chronic GVHD 
CLL chronic lymphocytic leukemia 
CNS central nervous system 
CRF case report form 
CR complete response 
CTCAE v. 4.[ADDRESS_843446] 
HIV human immunodeficiency virus 
IB Investigator’s Brochure 
IC50 half maximal inhibitor concentration 
ICF Informed consent form 
ICH International Conference on Harmonization 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843447] 
ITK IL-2 Inducible T-cell kinase 
IV Intravenous 
KPS Karnofsky performance status 
MCL mantle cell lymphoma  
mHAs minor histocompatibility antigens  
MMF mycophenolate mofetil 
MTD maximum tolerated dose 
NIH National Institutes of Health 
NRM non-relapse mortality 
PCI-[ZIP_CODE] ibrutinib or Imbruvica® 
PCR polymerase chain reaction 
PCYC Pharmacyclics LLC 
PFTs pulmonary function tests 
PK Pharmacokinetic 
PR partial response 
aPTT activated partial thromboplastin time 
PT prothrombin time 
QoL Quality of life 
QTc Corrected QT interval 
REB Research Ethics Board 
RP2D recommended phase [ADDRESS_843448] operating procedures 
t1/[ADDRESS_843449] upper limit of normal 
  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843450] report in 1957, allogeneic hema
topoietic cell transplant (HCT) has been refined 
from a dismal failure to a standard therapy for hematologic malignancies and hematopoietic 
progenitor cell disorders ( Thomas 1957). Allogeneic HCT can cure patients with chemotherapy 
resistant m
alignancies through graft versus tu mor effects generated by [CONTACT_183947]’s immune 
system against the recipi[INVESTIGATOR_841]’s tumor ( Appelbaum 2001 ). However, just as the donor’s immune 
system can sense and attack the recip
ient’s ma lignant cells, so can it sense and attack the 
recipi[INVESTIGATOR_841]’s normal tissues resulting in graft versus host disease (GVHD). 
Chronic GVHD (cGVHD) is a serious and life threat ening impediment to the otherwise curative 
potential of allogeneic hematopoetic st em cell transplantation (allo-HCT) ( Baird 2006;  Lee 2003 ; 
Pi[INVESTIGATOR_43221] 2011 ; Arai 2011). It is the mo st common long-te rm complication following allo-HCT, 
affecting 30-70% of patients who survive past the first 100 days ( Lee 2010 ), and it is a leading 
cause of non-relapse mortality (NRM) ( Lee 2008 ). Chronic GVHD is an important cause of late 
morbidity and mortality after allogeneic HCT ( Socie 1999 ; Lee 2002 ). Patien ts with active 
cGVHD are more likely to report ad verse general health, mental he alth, functional impairments, 
and pain than allo-HCT survivors without cGVHD ( Fraser 2006). Chronic GVHD is also 
associated with decreased quality of life (QoL
) and the continued need for immunosuppressive 
medications (Fraser 2006; Sutherland 1997 ; Lee 2003; Lee 2006 ). Chronic GVHD can appear as 
early as 3 months following stem cell transplant  (SCT), although its m
anifestations may take 
much longer to appear, and any organ system can be affected (Mohty 2008). The dist inct 
cGVHD findings are collagen-vascular cha nges involving the skin, mouth, genitalia, 
gastrointestinal tract, lung, muscle fascia, and joints ( Filipovich 2005 ). Pathologically, cGVHD 
is characterized by [CONTACT_183949] ( Shul
man 2006).  
Risk factors for developi[INVESTIGATOR_631935], use of peripheral blood stem
 cells 
versus bone marrow, and lack of T-cell depletion ( Lee 2008 ). Wh ile limited progress related to 
prevention or treatment of cGVHD has been made, the development of the National Institutes of 
Health (NIH) Consensu s Criteria for grading and stagi ng cGVHD represents a significant 
advancement, providing a clinically useful se verity measure for use in clinical trials 
(Filipovich 2005 ). Therapy for cGVHD is limited to broad-spectrum  immune inhibitors which, in 
addition to lacking efficacy, increase the risk of  tumor relapse by [CONTACT_631958] 
(GVT) immunity ( Holler 2007 ). The initial tre atment is corticosteroids, but half of patients 
require second-line treatment, for which there is no standard of care. NRM increases from 12% 
to 27% for patients requiring a therapy change within 4 months of the start of treatment 
(Flowers 2008b ). The median treatment duration is 2-3 years, contributing further to morbidity 
(Syrjala 2012 ). There is a direct clini cal need for new therap ies which suppress the autoimmune 
and fibrotic cascades yet preserve GVT and immunity against infection. 
 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843451] Disease 
The immunopathology unde rlying development of cGVHD is poorly understood. Mouse models 
typi[INVESTIGATOR_631936]: auto antibody production, pro-fibrotic pathways, and 
defective thymic function ( Schroeder 2011 ). Thymic damage result s in dysfunctional negative 
selection of autoreactive T cells. Recipi[INVESTIGATOR_841] B cells are activated by [CONTACT_631959]2 
cytokines, and present proce ssed antigens to donor CD4+ T cells, which co-stimulate B cells to 
produce autoantibodies and additi onal stimulatory cytokines ( Morris 1990; Shimabukuro- 
Vornhagen 2009 ). T and B cells then clonally expand, fo rming memory and effector cells which 
traffic to target organ sites, mediating damage  through cytokine-mediated fibrosis. Activated T 
and B cells release inflammatory  and fibrosing cytokines, such  as IL-13, IL-10, and IL-3. In 
addition, activated macrophages produce transforming growth factor-β  (TGF-β ), stimulating 
collagen production from fibroblasts which lead s to a scleroderma-like syndrome (Schroeder 
2011). T cells are known to be critically important  in the development of cGVHD. Higher rates 
of cGVHD are seen in recipi[INVESTIGATOR_631937]-stimulating factor m obilized peripheral b
lood grafts 
compared with marrow grafts and in pa tients who receive a higher T cell dose ( Anasetti 2011 ). 
In vivo T cell depletion with anti-t hymocyte globulin or alemtu zumab can reduce the incidence 
of cGVHD, but at the cost of  higher rates of viral or opportu nistic infections and relapse 
(Hale 2012; Perez-Simon 2002). More recently, alloreactive B ce ll have been implicated in the 
development of cGVHD ( Miklos 2005; Miklos 2004). 
1.3. B Cells and the Development of cGVHD 
Alloreactive B cells are associated with cGVHD and, in particular, antibodies against minor 
histocompatibility antigens (mHAs) correlate with cGVHD incidence ( Miklos 2005; 
Miklos 2004 ). HY antibodies develop in male patients who receive their H
CT from a female 
donor. HY IgG positive patients have a cGVHD incidence of 89% and 0% relapse at 5-years 
post-transplant while those w ithout HY IgG have
 a 31% incidence of cGVHD and 48% relapse 
at 5 years (Miklos 2005; Miklos 2004). HY an tigens are mHAs found on the Y chromosome 
with homologous proteins  on the X chromosom
e (Ofran 2010) and by [CONTACT_631960]-mis
matched transplants an  allo-immune response representing cGVHD was 
studied. The rationale is that  lymphocytes from the female  donor graft, which lack a Y 
chromosome, recognize the HY mHAs as foreign, thus producing HY specific antibodies. This 
coordinated HY antibody response in the context of  cGVHD suggests that specific anti-B cell 
therapy may be effective in treating cGVHD. In  support of this hypothesis, rituximab infused 
2-[ADDRESS_843452] in male patients wi th female donors, prevents development of HY 
antigen-specific alloreactive B cells and IgM antibody ( Arai 2012).  
B-cell depletion therapy using rituximab in newly diagnosed cGVHD is  s
teroid sparing, but 
cGVHD frequently recurs as alloreactive B cells recur 9 −12 months after rituximab treatment. 
The Miklos group reported at the American So ciety for Blood and Marrow Transplantation 
(ASBMT) 2013 Meeting a Phase 2 study testing the e fficacy of rituximab and corticosteroids in 
35 patients with new onset cGVHD ( Sahaf 2013 ). The clinically significant primary endpoint of 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 19 achieving NIH partial and complete responses and prednisone taper <0.25 mg/kg/day were seen 
in 15/35 patients (43%, 13 complete response [CR]; 2 partial response [PR]) at 6 months and 
remained 15/35 (43%, 11 CR, 4 PR) through [ADDRESS_843453], the new onset cGVHD study showed that 
allogeneic HY-specific B cells and antibodies  were depleted but uniformly recurred 9 −12 months 
after rituximab ( Sahaf 2013 ). 
In addition to the production of alloantibodies, B cells contribute to the immune response via 
antibody-independent processes, such as an tigen presentation, cy tokine and chem
okine 
production, and immunoregulatory function ( Sahaf 2013 ). Following activation v ia the B-cell 
receptor (BCR) signaling pathways, B cells become potent antigen-presenting cells. Activated B cells produce a variety of inflammatory cytokines, and antigen presentation by [CONTACT_183950] B cells is critical in autoimmune disorders ( Shimabukuro-Vornhagen 2009 ). Dysfunctional B cells 
have been identified in cGVHD, wher
e patients have a relatively higher number of activated 
memory B cells, higher levels of B cell-activating factor of the tumor necrosis family (BAFF), 
and donor-derived alloantibodies ( Sarantopoulos 2009 ). Immunoglobin heavy chain (IGH) 
diversity, as evaluated by [CONTACT_5019]- throughput sequencing, is decrea sed at [ADDRESS_843454] am
ong patients who subsequently develop GVHD, suggesting impaired B cell clonotype 
diversification (Logan 2013).  
1.4. Other Lymphocytes and the Development of cGVHD 
The Ohio State group recently evaluated the influence of lymphocyte rec onstitution at days [ADDRESS_843455] on subsequent  development of cGVHD through use of an 
extens
ive immune reconstitution flow cytometric “immunome” assay. Pa tients who developed 
cGVHD had a larger increase in CD4+ T cells and a smaller increase in CD8+ T cells over time 
compared with patients who did not, s uggesting a selective expansion of CD4+ T cells. Further, 
an increase in percentages of activated B cells was noted. An increase in CD4+ cells is associated 
with an inflammatory phenotype, and a Th2-skewed  proinflammatory response may contribute to 
B cell activation. The pres ence of increased CD4+/CD193+ cells among patients with cGVHD 
supports the notion of a Th2-skewed phenotype, as CCR3 is preferentially expressed on Th2 
cells. While a Th2-skewed phenotype has been de monstrated in mouse models of cGVHD, this 
has not been definitively established in humans (Jaglowski, 2012).  1.5. Current Therapi[INVESTIGATOR_631938] y therapy for cGVHD. An early double-blind, random 
ized trial 
compared prednisone and placebo with prednisone and azathioprine as early treatment for 
standard risk cGVHD ( Sullivan 1988). Non-relapse mortality was significantly lower (21% vs. 
40%, p=0.003) and overall survival  significantly higher (61% vs. 47%, p=.03) in the prednisone 
and placebo arm
, establishing prednisone as th e primary therapy for cGVHD. Corticosteroid 
treatment may require several months before the fu ll benefits are seen. Duri ng this time, patients 
may experience the side effects of corticosteroids:  more frequent infections, avascular necrosis, 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843456] s, altered mental states, and disturbed sleep patterns 
(Sullivan 1988). Koc et al. tested the a ddition of cyclosporine to prednisone as a steroid-sparing 
agent and observed fewer complications such as avascular necrosis from steroid use ( Koc 2002 ). 
However, the relapse rate was increased resulting in no overall survival benefit compared to the 
prednisone only arm.  
Second line therapy for cGVHD patie nts who fail corticosteroids is  not well established. The 
addition of mycophenolate mofetil (MMF) was compar ed to standard therapy in a double blind 
randomized trial ( Martin 2009 ). This trial was stopped early becau se of decreased survival in the 
MMF arm, leading the investig ators to recommend against adding MMF to cGVHD therapy. A 
randomized trial comp
aring the addition of ex tracorporeal photopheresi s (ECP) to standard 
therapy demonstrated a small but significant benefit (improvement in 4/48 vs. 0/47 patients, 
p=0.04) ( Flowers 2008a
). However, ECP requires a motivat ed patient to endure 3-4 hours 
vascularly connected to a pheresi s pump on a weekly to monthly basis and may not be feasible 
fo
r all patients. Other therapeutic options include thalidomide ( Parker 1995; Kulkarni 2003), 
hydroxychloroquine ( Gilman 2000 ), sirolimus ( Couriel 2005 ; Johnston 2005), and rituximab 
(Ratanatharathorn 2003; Cutler 2006; Canninga-van Dijk 2004) . These have complete response 
rates ranging from 10-35% and none has been shown to be clearly superior. 
A recently published single institution study deve loped a new approach for evaluating clinical 
trial endpoints for testing therapi[INVESTIGATOR_306128]-line treatm
ent of cGVHD ( Inamoto 2013 ). The 
primary study endpoint was failure free survival (FFS) defined as the absence of a third line 
therapy, NRM, and recurrent malignancy. This was a retrospective study of  [ADDRESS_843457] 0.5 mg
/kg/day be fore second line treatment, were on systemic 
immunosuppressive therapy when the second line therapy was initiated, and had received second 
line therapy due to cGVHD progression after at least one week of initial therapy or due to lack of 
improvement after at least two weeks of initial  therapy. FFS was reported at 56% at 6 m
onths 
and at 45% at 12 months from the start of second line therapy (Inamoto 2013). With 48 months of follow-up, only 15% of patients were able to successfully withdraw from all immuno-suppressive therapy. The major cau se of FFS was treatment change  (ie, need for third line 
therapy) and the study results have set a benchmark for second line cGVHD therapy (Inamoto 2013).  
1.6. Ibrutinib Overview 
Ibrutinib (I
MBRUVICA®) is a first-in-class, potent, oral ly administered covalently-binding 
inhibitor of Bruton’s tyrosine  kinase (Btk) co-developed by [CONTACT_183953] & Development LLC (collectively referred to as the Sponsor) for the treatment of B-
cell malignancies.   
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 21 Ibrutinib has been approved in many regions including the US and EUfor indications covering 
the treatment of patients with mantle cell ly mphoma (MCL) and chronic lymphocytic leukemia 
(CLL) who have received at le ast one prior therapy, first-line treatment of patients with CLL 
with a deletion of the short arm of chromosome 17 (del17p) or a TP53 mutation, and patients 
with Waldenström’s macroglobulinemia. Ibrutinib is currently under investigation in various 
indications as a single agen t and in combinations.  
B cells are lymphocytes with multiple functions in the immune response, including antigen 
presentation, antibody production, and cytokine  release. B-cells express cell surface 
immunoglobulins comprising the B- cell receptor (BCR), which is  activated by [CONTACT_375826]. Antigen binding induces receptor aggr egation and the cluste ring and activation of 
multiple tyrosine kinases, which in turn act ivate further downstream signaling pathways 
(Bishop 2003).  
For the mo
st comprehensive nonclinical and clin ical information regarding ibrutinib background, 
safety, efficacy, and in vitro and in vivo preclinical activ ity and toxicology of ibrutinib, refer to 
the latest version of the ibrutinib Investigator's Brochure. 
1.7. Summary of Nonclinical Data 
For the most com
prehensive nonclinical and clini cal information regarding ibrutinib, please refer 
to the current version of the Investigator's Brochure. 
1.7.1. Pharmacology  
Ibrutinib was designed as a selective and covalent inhibitor of the Btk ( Pan 2007). In vitro, 
ibrutinib is a potent inhibitor of Btk activity (IC50 = 0.39 nM). The irreversible binding of 
ibrutinib to cysteine-481 in the active site of Btk results in su
stained inhibition of Btk catalytic 
activity and enhanced selectivity over other kinases that do not cont ain a cysteine at this position. 
When added directly to human whole blood, ibruti nib inhibits signal tran sduction from the B-cell 
receptor and blocks primary B-ce ll activation (IC50 = 80 nM) as assayed by [CONTACT_14181]-IgM stimulation 
followed by [CONTACT_398]69 expression ( Herman 2011).  
For more de
tailed and comprehensive inform ation regarding nonclinical pharmacology and 
toxicology, please refer to the current Investigator’s Brochure . 
1.7.2. Toxicology 
In safety pharmacology assessm
ents, no treatment -related effects were ob served in the central 
nervous system (CNS) or respi[INVESTIGATOR_631939] d. Further, no treatment-
related corrected QT interval (QTc) prolongation effect was obser ved at any tested dose in a 
cardiovascular study using te lemetry-monitored dogs.  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843458] potential for human toxi city with ibrutinib is predicted to be in lymphoid tissues 
(lymphoid depletion) and the gastrointestinal tract (soft feces/diarrh ea with or without 
inflammation). Additional toxicity findings seen in only one species with no observed human 
correlate in clinical studies to date include pancreatic aci nar cell atrophy (rat), minimally 
decreased trabecular and cortical bon e (rat) and corneal dystrophy (dog).  
In vitro and in vivo genetic toxi city studies showed that ibruti nib is not genotoxic. In a rat 
embryo-fetal toxicity study ibrutinib admini stration was associated with fetal loss and 
malformations (teratogenicity) at ibrutinib dos es that result in a pproximately 6 times and 
14 times the exposure (AUC) in patients administ ered the dose of 560 mg  daily, respectively.  
[IP_ADDRESS]. Carcinogenesis, Mutagenesis,  Im pairment of Fertility 
Carcinogenicity studies have not  been conducted with ibrutinib. 
Ibrutinib was not mutagenic in a bacterial mutage nicity (Ames) assay, was not clastogenic in a 
chromosome aberration assay in mammalian (CHO) cells, nor was it clastogenic in an in vivo bone marrow micronucleus assay in mice at doses up to 2000 mg/kg. 
Fertility studies with ibrutinib have not been conducted in anim als. In the general toxicology 
studies conducted in rats and dogs , orally administered ibrutinib did not result in adverse effects 
on reproductive organs. 
1.8. Summary of Clinical Data 
For the mo
st comprehensive clinical information regarding ibrutinib, please refer to the current 
version of the Investigator's Brochure.  
1.8.1. Pharmacokinetics and Product Metabolism 
Following oral admi
nistration of ibrutinib at doses ranging from 1.25 to 12.5 mg/kg/day as well 
as fixed dose levels of 420, 560, and 840 mg/day, exposure to ibrutinib increased as doses 
increased with substantial intersubject variability. The mean half life (t 1/2) of ibrutinib across 
3 clinical studies ranged from 4 to 9 hour s, with a median time to maximum plasma 
concentration (T max) of [ADDRESS_843459] dose exposure. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 23 The results of human mass balance study of [14C]-ibrutinib conducted in six healthy male 
subjects demonstrated that less than 10% of the total dose of [14C]-ibrutinib is renally excreted, 
whereas approximately 80% is recovered in feces. Subjects with mild and moderate renal 
insufficiency (creatinine cleara nce >30 mL/min) were eligible to enroll in Study PCYC-1102-CA 
in which pharmacokinetic (PK) assessments were  included. No dose adjustment is needed for 
mild or moderate renal impairment (greater th an 30 mL/min creatinine clearance). There is no 
data in patients with severe renal impairment or patients on dialysis. In  a hepatic impairment 
study, data showed an increase in  ibrutinib exposure. Following single dose administration, the 
AUC of ibrutinib increased 2.7-, 8.2- and 9.8-fold in subjects w ith mild (Child-Pugh class A), 
moderate (Child-Pugh class B), and severe (Child -Pugh class C) hepatic impairment compared to 
subjects with normal liver function. The safety of  ibrutinib has not been evaluated in patients 
with hepatic impairment. 
1.8.2. Summary of Clinical Safety  
A brief summary of safety data from
 monothera py and combination ther apy studies is provided 
in below. For more comprehensive safety inform ation please refer to the current version of the 
IB. Additional safety information may be avai lable for approved indications in regional 
prescribing labels where the study is conducted (eg, USPI, SmPC).  
[IP_ADDRESS]. Monotherapy Studies 
Pooled safety data for a total of [ADDRESS_843460] frequently reported treatment-emergent a dverse events (TEAEs) in subjects receiving 
ibrutinib as monotherapy (N=1071): 
Most frequently reported 
TEAEs >10%   Most frequently reported Grade 3 or 4 TEAEs >2%  Most frequently reported Serious TEAEs >1%  
Diarrhea Neutropenia Pneumonia 
Fatigue Pneumonia At rial fibrillation 
Nausea Thrombocytopenia Febrile neutropenia 
Cough Anemia Pyrexia 
Anemia Hypertension    
Pyrexia Atrial fibrillation  
Neutropenia    
 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 24 1.8.3.  Risks 
[IP_ADDRESS]. Bleeding Related Events 
There have been reports of hemorrhagic events in  subjects treated with ibrutinib, both with and 
without thrombocytopenia. These include minor hemorrhagic events such as contusion, epi[INVESTIGATOR_3940], 
and petechiae, and some
 major hemorrhagic ev ents, some fatal, incl uding gastrointestinal 
bleeding, intracranial hemorrhage, and hematuria. Use of ibrutinib  in subjects requiring other 
anticoagulants or medications that inhibit platelet function may increase the risk of bleeding. 
Subjects with congenital bleeding diat hesis have not been studied. See Section 6.2.4 for guidance 
on concomitant use of anticoagulants, antiplate let therapy and/or supplements. See Section 6.4 
for guidance on ibrutinib ma
nagement with surgeries or procedures.   
[IP_ADDRESS]. Cytopenia 
Treatme
nt-emergent grade 3 or 4 cytopenias (neu tropenia, thrombocytopenia, and anemia) were 
reported in subjects treat ed with ibrutinib.  
[IP_ADDRESS].
 Atrial Fibrillation  
Atrial fibrillation and at rial flutter have been reported in  subjects treated with ibrutinib, 
particularly in subjects with cardiac risk f
actors,  acute infections, and a pr evious history of atrial 
fibrillation. For atrial fi brillation which persists, consider th e risks and benefits of ibrutinib 
treatment and follow the protocol  dose modification guidelines (see Section [IP_ADDRESS]). 
[IP_ADDRESS]. Diarrhea 
Diarrhea is the most frequen tly reported non-hematologic AE with ibrutinib monotherapy and 
combination therapy. Other frequently reported g
astrointestinal events include nausea, vomiting, 
and constipation. These events are rarely seve re. Should symptoms be severe or prolonged 
follow the protocol dose m odification guidelines (see Section [IP_ADDRESS]).  
[IP_ADDRESS]. Infections 
Fatal and non-fatal infections have  occurred with ibruti nib therapy. At least 25%  of subjects with 
MCL and 35% of subjects with CLL had grad e 3 or greater infec tions per NCI Common 
Terminology Criteria for Adverse Events (CTCAE v.4.03). The most commonly reported 
infections include pneumonia, ce llulitis, urinary tract infection and sepsis. Although causality has 
not been establishe
d, cases of progressive multif ocal leukoencephalopathy (PML) have occurred 
in patients treated with ibrutinib. 
[IP_ADDRESS]. Second primary Malignancies 
Second primary malignancies, most frequently skin  cancers, have occurred in subjects treated 
with ibrutinib. Second primary m
alignancies including non-skin carcinomas have occurred in 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843461] frequent second primary malignancy was non-
melanoma skin cancer. 
[IP_ADDRESS]. Rash 
Rash has been commonly reported in subjects trea ted with either single agent ibrutinib or in 
combination with chemotherapy. In a randomi zed Phase 3 study (PCYC-1112-CA), rash 
occurred at a higher rate in the ibrutinib arm than in the contr
ol arm. Most rashes were mild to 
moderate in severity.  
1.9. Study Rationale 
1.9.1. Ibrutinib (Btk Inhibitor) Ta rgets of Interest in cGVHD 
Ibrutinib is a first-in-class, potent, orally admi nistered covalently-bindi ng inhibitor of Bruton’s 
tyrosine kinase (Btk) and may be a more
 potent B cell malignancy drug than rituximab 
(Advani 2012; By[CONTACT_26752] 2013). Btk is a critical intermediate in BCR signaling ( Mohamed 2009). It is 
a non-receptor tyrosine kinase belonging to the Te c family of kinases (TFKs), and critical for B 
cell processes effected by [CONTACT_488260] (Mohamed 2009) . Individuals who lack functioning Btk lack 
circulating B cells and are unable to produce immunoglobulins or mount humoral immune 
responses ( Satterthwaite 2000 ). BCR ligation leads to Btk ac tivation which subsequently 
phosphorylates phospholipase C γ2 (PLCγ2) triggering a series of downstream
 events including 
transcriptional regulation involving NF- κB and NFAT (Mohame
d 2009). Btk appears to regulate 
B cell survival by [CONTACT_631961]-R signaling (Shinners 2007). 
Ibrutinib is also an irreversible inhibitor of in terleukin-2 inducible kinase  (ITK). ITK is involved 
in proximal T-cell receptor (TCR) signaling whic h activates the signaling cascade that include
s 
NFAT, NFkB, and MAPK pathways resulting in T cell activation. ITK has a dominant role in the 
activation of Th2 cells, but not in Th1 cells. 
This is an exploratory study and other than anecdotal reports there is no clinical da
ta on the use 
of ibrutinib in cGVHD. 
1.9.2. Ibrutinib in Murine cGVHD Models 
Investigators at Ohio State University and Un iversity of Minnesota have studied cGVHD in 
mouse models (unpublished data; manuscript submitted). In the LP/J →C57BL/6 model of 
sclerodermatous cGVHD, sympto
ms become appa rent between days 20-25 and peak between 
days 37− [ADDRESS_843462]. Ibrutinib, vehicle, or cyclos porine treatment was initiated on randomized 
cohorts at day 25, after the majo rity (72%) of mice had clinical signs of cGVHD. By [CONTACT_4475] 39, 
ibrutinib treated mice displayed a profound lack of  signs of cGVHD that were observed in both 
the vehicle and cyclosporine treatment groups including hair loss, hunched posture, and dermal 
lesions. Mice were blindly assessed using a scale which quantit atively grades cGVHD on a scale 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 26 from 0 to 19. Using this scale, it was docum ented that mice treated with ibrutinib had 
significantly fewer manifestati ons of cGVHD compared with ve hicle treatment (p=0.0184). In 
addition, ibrutinib significantly extended median time to progression by 14 days; 33% (6 of 18) 
of ibrutinib treated mice did not progress as compared to 12% (2 of 18) of mice receiving vehicle 
and 10% (1 of 11) of mice receivi ng cyclosporine 10mg/kg/day (p<0.02). 
In addition to the sclerodermatous cGVHD model, th ese investigators also evaluated ibrutinib in 
a murine model of alloan tibody driven multi-organ syst em cGVHD (MHC disparate, 
C57BL/6→B10.BR). This murine model includes ev idence of bronchiolar obliterans (BO). 
Ibrutinib treatment in this model restored pulm onary function defects, reduced germinal center 
reactions, and reversed lung and liver fibrosis. 
1.9.3. Justification of Study Design and Dose Rationale 
While rituxima
b has shown efficacy in a prophylact ic role against cGHVD, rituximab used with 
corticosteroids has provided only partial efficacy  in steroid-refractor y or new onset cGVHD. 
Furthermore, rituximab alone does not deplete alloreactive B cells once cGVHD has developed. 
Ibrutinib has the potential to improve upon the efficacy of rituximab due to its unique 
mechanism of action on B cells in combination w ith its potential to re verse ITK polarization, 
thus causing a skewing away from a Th2 cytokine profile. 
Btk occupancy >95% has been demonstrated in  all patients who rece ived Ibrutinib dosed 
2.5 mg/kg/day or higher. Modest toxicity ha s been reported at 420 and 840 mg daily. Common 
AEs reported were gastrointestinal upset (dia rrhea, nausea, vomiting) , fatigue, respi[INVESTIGATOR_58776], and rash. Because these AEs may overlap with cGVHD manifestations, a 
conservative dose of 420 mg will be used as the starting does for this  trial. This dose is currently 
approved for use in relapsed/refractory CLL with  an acceptable safety profile. At 420 mg daily, 
Dubovsky et al. (2013) reporte d 40-80% ITK occupancy ( Dubovsky 2013). If the 420 mg dose 
demonstrates unacceptable toxicity in the cGVHD population then the dose will be lowered to 
280 mg/day which is also expected to produce full BTK occupancy. If further dose reduction is 
required due to toxicity, a dose of [ADDRESS_843463] dose 
recommended in the FDA package insert for ibrutinib. 
2. STUDY OBJECTIVE   
2.1. Primary Objective 
Phase 1b:  
To evaluate the safety and tolerability of ibrutinib in ster oid dependent/refractory cGVHD.  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 27 Phase 2:  
To evaluate the clinical efficacy of ibrutin ib in steroid dependent/refractory cGVHD by 
[CONTACT_631952] (NIH-d efined complete [CR]  and partial response 
[PR]). 
2.2. Secondary Objectives 
Phase 1b:  
• To evaluate the clinical efficacy of ibrutin ib in steroid dependent/refractory cGVHD by 
[CONTACT_35755]: 
o Best overall cGVHD response (NIH-defined CR and PR) 
o Rate of sustained response for at least 5 months 
o Duration of response (DOR) 
o Corticosteroid requirement changes over time 
o Change in symptom burden measured by [CONTACT_631962] 2:  
• Rate of sustained response for at least 5 months 
• Duration of response (DOR) 
• To evaluate the safety and tolerability of  ibrutinib in steroid dependent/refractory 
cGVHD  
• To evaluate the impact of ibrutinib on co rticosteroid requirement changes over time 
• To evaluate ibrutinib treatment effect on ch ange in symptom burden measured by [CONTACT_631963] 
2.3. Exploratory Objective(s)  
Phase 1b and Phase 2:  
• To evaluate the clinical effi cacy of ibrutinib by [CONTACT_631964] (FFS) at 
6 and 12 months 
• To evaluate photographic changes in skin and mucocutaneous manifestations with 
ibrutinib treatment 
• To determine the pharmacokinetics (PK) of  ibrutinib in subjects with cGVHD 
• To determine the alloreactive B cell deplet ion, T-helper cell composition, and BTK/ITK 
blockade including: 
o HY antigen-specific allogeneic B cell deple tion in males who receive allo-HCT from 
a female donor. 
o Quantification of HY IgG and IgM alloreactiv e antibodies in males who receive allo-
HCT from a female donor. 
o BTK and ITK binding site occupation. 
o B cell depletion, flow cytometric analysis  of T-helper cell composition, T and B cell 
cytokine analysis, and phosphoflow analysis of CD4+ T-cell ITK blockade. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 28 3. STUDY DESIGN   
3.1. Overview of Study Design 
The primary objective of this Phase 1
b/2 study is to  evaluate the safety and efficacy of ibrutinib 
in treating subjects with steroi d dependent/refractory cGVHD.  
The study will be conducted in two phases. 
Phase 1b will be an open-label, safety study to determine the proper dose to take into the Phase [ADDRESS_843464] dose of ibrutinib (420 mg) but includes potential dose reduction(s) (to 280 mg and 140 mg) if dose limiti ng toxicities (DLTs) 
are detected (see Section 5.2.2 below). Depending on the incidence of DLTs, between 
6-[ADDRESS_843465] 
udy. Once the recommended Phase 
2 dose (RP2D) is determined, Phase 2 will commence. 
Phase 2 will be an open-label study using the RP2D determined in Phase 1b. Enrollment will 
continue until a total of approximately 40 subjects (from both Phase 1b and Phase 2) receive the 
RP2D dose. 
Subjects will be treated continuously with ibru tinib and efficacy will be evaluated including: 
• Best overall cGVHD response accordi ng to NIH-defined CR and PR 
• Rate of sustained response for at least 5 months 
• Duration of response (DOR) 
• Corticosteroid requirement changes over time 
• Change in symptom burden measured by [CONTACT_631965] 
• Photographic changes in skin a nd mucocutaneous manifestations 
Both Phase 1b and [ADDRESS_843466] one of the following categories: 
• >25% body surface area (BSA) NIH-define d criteria “Erythematous rash” 
• >[ADDRESS_843467] dos e of study treatment un til DLT in Phase 1b or 
until disease progression, unacceptable toxicit y, recurrence of underlying malignancy, or study 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843468] discontinues ibrutinib treatment:  
• Subjects who discontinue for reasons other than  disease progression (ie, for adverse event 
or Investigator decision), will complete an End-of-Treatment Visit (30 ± [ADDRESS_843469] dose of ibrutinib) and will be followed until death, lost to follow-up, consent 
withdrawal, or study end, whichever occurs first: 
o Continued disease evaluations 
o Follow-up for recurrence of malignancy 
o Follow-up for new cGVHD treatments 
• Subjects who discontinue due to disease progr ession will complete an End-of-Treatment 
Visit and be followed for survival status.  
3.2. Study Schema 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 Screening Phase 
(within [ADDRESS_843470] study treatment) 
Assess Eligibility Criteria- obtain Sponsor approval to enroll  
Enrollment 
Subjects must start ibrutinib within 72 hours of enrollment
Treatment Discontinuation 
Complete End-of-Treatment Visit 
Follow-up Phase 
[until death, lost to follow up, consent withdrawal, or 
study end, whichever occurs first] 
 
Prior to Disease Progression (if applicable):  
• Continue disease evaluations 
• Follow for the reoccurrence of malignancy 
• subsequent cGVHD therapi[INVESTIGATOR_631940]:  
• Survival  Treatment Phase 
Ibrutinib at 420, 280, or 140 mg/day 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary an d Confidential Page 30 3.3. Phase 1b Safety/DLT Assessment 
Phase 1b will be conducted with up to 27 subj ects enrolled depending on the occurrence of 
DLTs. The starting dose will be 420 mg and a modified 3+3+
3 design will be used (see 
Section 5.2.1 and Section 3.3.1) to assess DLTs. If DLTs ar e unacceptably high then the dose of 
ibrutinib ma
y be reduced sequentially to [ADDRESS_843471] not experienced 
a DLT in Phase 1b (after 4 weeks of ibrutinib treatment) may continue into Phase [ADDRESS_843472] satisfy all of the following inclusion 
criteria. 
1. Steroid dependent/refractor y classic cGVHD defined at  any time post-HCT as: 
a) Dependent disease – Persiste nt cGVHD manifestations requi ring a glucocorticoid dose 
≥ prednisone 0.25 mg/kg/day (0.5 mg/kg orally every other day or equivalent) for at least 
12 weeks. 

Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 31 b) Refractory disease - Progre ssive cGVHD manifestations despi[INVESTIGATOR_12847] a 
glucocorticoid dose ≥ prednisone 0.5 mg/kg/day (1 mg /kg orally every other day or 
equivalent) for at least [ADDRESS_843473] 
56 days before starting ibrutinib. 
5. Chronic GVHD manifestations ( Appendix B ) that can be followed on physical or laboratory 
exam including at leas
t one of the following criteria:  
• >25% BSA NIH-defined criter ia “Erythematous rash”  
• >4 total mouth score by [CONTACT_4289]-defined criteria  
6. Clinically stable or worsening cGVHD between Screening and Day 1 cGVHD response 
assessment (see Section 7.1.3 for details). 
7.
 ≥18 years of age 
8. Life expectancy ≥6 months 
9. Karnofsky performance status ≥60 (see Appendix C ).  
10. Adequate hepatic and rena l function as defined as: 
a) Serum creatinine ≤1.[ADDRESS_843474] 
b) Aspartate aminotransferase (AST), alanin e aminotransferase (ALT) and alkaline 
phosphatase ≤ [ADDRESS_843475] or of non-hepatic origin, such as hemolysis 
c) Total bilirubin ≤[ADDRESS_843476] (unless bilirubin rise is due  to Gilbert’s syndrome or of non-
hepatic origin) 
d) Estimated Creatinine Clearance ≥30 mL/min (using Cockcroft-Gault formula) 
11. Adequate hematological function defined as : 
a) Absolute neutrophil count (ANC) ≥1.0 x 109/L and off growth factor support x 7 days 
b) Platelets ≥30 x 109/L and no transfusion support x 7 days 
c) Hemoglobin ≥8 g/dL and no transfusion or growth support x 7 days 
12. PT/INR <1.[ADDRESS_843477] and PTT (aPTT) <1.[ADDRESS_843478] (unless abnormalities are unrelated to 
coagulopathy or bl eeding disorder). 
13. ≤6 stools per day 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 32 14. Oxygen saturation after exertion maintained at ≥ 88% on room air. If not, forced expi[INVESTIGATOR_184849] 1 second (FEV1) ≥50% on pulmonary function tests performed within 6 months of 
study entry.  
15. Ability to understand and willingness to sign a written informed consent form (ICF).  
16. Myeloablative or non-myeloablative allogeneic  hematopoietic cell transplant for underlying 
hematological disease. 
17. Female subjects who are of non-reproductive pote ntial (ie, post-menopausal by [CONTACT_969] - no 
menses for ≥1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR 
history of bilateral oophorectomy). Female subjects of reproductive po tential must have a 
negative serum pregnanc y test upon study entry. 
18. Male and female subjects of reproductive po tential who agree to use highly effective 
methods of birth control (eg, c ondoms, implants, injectables, co mbined oral contraceptives, 
some intrauterine devices [IUDs],  complete abstinence1, or sterilized partner) during the 
period of therapy and for [ADDRESS_843479] meet NONE of the following exclusion 
criteria: 
1. Known or suspected active acute GVHD 
2. Received any investigational agents ≤28 days before starting ibrutinib. 
3. Current treatment with sirolimus AND either cyclosporine or tacrolimus. 
4. History of treatment with a tyro sine kinase inhibitor (eg ima tinib) purine analogs, or other 
cancer chemotherapy in the 4 week s prior to starting ibrutinib. 
5. Currently active, clinically significant cardi ovascular disease, such as uncontrolled 
arrhythmia or Class 3 or 4 congestive hear t failure as defined by [CONTACT_631966]; or a history of myocardi al infarction, unstable angina, 
or acute coronary syndrome within  6 months prior to randomization. 
6. Any uncontrolled active systemic infection or in fection requiring systemic treatment that was 
completed ≤[ADDRESS_843480]-tran splant lymphoproliferative 
disease.  
8. History of other malignancy (not including the underlying malignancy that was the indication 
for transplant), with the following exceptions: 
                                                   
[ADDRESS_843481]. 
http://www.hma.eu/fileadmin/dateien/Human_Medicines/01 
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 33 • Malignancy treated with curative intent and with no evidence of active disease present for 
more than 3 years prior to sc reening and felt to be at low risk for recurrence by [CONTACT_142940]; 
• Adequately treated nonmelanomatous skin cancer or lentigo maligna melanoma without 
current evidence of disease; 
• Adequately treated cervical carcinoma in situ without current evidence of disease. 
9. Subject is pregnant, breast-feed ing, or of childbearing potential  without a negative serum or 
urine pregnancy test within [ADDRESS_843482] not willing to comply with treatment or response evaluation. 
11. Moderate or severe hepatic impair ment (Child-Pugh classification, see Appendix K ). 
12.
 Subject has a concurrent illness which in the op inion of the investigator may interfere with 
the treatment and evaluation of the patient. 
13. Concomitant use of warfarin or  other Vitamin K antagonists  
14. Subject has a known allergy or hype rsensitivity to ibrutinib. 
15. Vaccinated with live, attenuated vaccines wi thin [ADDRESS_843483] dose of ibrutinib. 
16. Known bleeding disorders (eg, von Willebrand’s disease or hemophilia). 
17. History of stroke or intracranial hemorrh age within 6 months prior to enrollment. 
18. Known history of human immunodeficiency virus (HIV) or active with hepatitis C virus 
(HCV) or hepatitis B virus (HBV). Subjects w ho are positive for hepa titis B core antibody, 
hepatitis B surface antigen, or hepatitis C anti body must have a negative polymerase chain 
reaction (PCR) result before enrollment. Those who are PCR positive will be excluded. 
19. Major surgery within [ADDRESS_843484] dose of ibrutinib. 
20. Concurrent use of a strong cytoch rome P450 (CYP) 3A inhibitor ( Appendix I ). 
21.
 Unable to swallow capsules or malabsorpti on syndrome, disease si gnificantly affecting 
gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or  partial or complete bowel obstruction. 
22. Unable to understand the purpos e and risks of the study and to  provide a signed and dated 
informed consent form (ICF) and authorizati on to use protected health information (in 
accordance with national and local subject privacy regulations). 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843485] ed: 140 mg/day, 280 mg/day and 420 mg/day. The 
starting dose will be 420 mg/day and the dose wi ll be modified based on the dose limiting 
toxicities (DLTs). 
Phase 1b will follow a modified 3+3+[ADDRESS_843486] 28 days of study 
treatment is <33%. Before determining the RP2D, [ADDRESS_843487] 
completed the DLT observation period which is defined as 28 days of therapy. Using the 
modified 3+3+3 design, the maximum tolerated dose (MTD) is exceeded when ≥3 out of 
9 subjects in a dose level experi ence a DLT. If there are 3 DLTs  at a dose level, the MTD is 
exceeded and then the next lower dose level will be enrolled.  
Enrollment in a dose level will proceed as follows: 
• If no DLT is observed during the DLT observati on period in the initial 3 subjects of a 
dose level, then a second group of 3 subjects will be enrolled at the same dose level for a 
total of 6 subjects. If 0-1 DLT occur out of 6 subjects, then this dose will be the RP2D. If 
2 DLTs occur out of 6, then the dose level cohort will be expanded to enroll a total of 
9 subjects. If no further DLTs occur then this dose will be the RP2D. 
• If [ADDRESS_843488] 6 subjects. If no further 
DLT(s) are observed, then this dose will be the RP2D. If 2 DLTs are observed out of 
6 subjects, then the dose level will be expanded to enroll a total of 9 subjects. If no 
further DLTs are observed in this group of subjects then this dose will be the RP2D. 
• If 2 DLTs are observed in the in itial 3 subjects, then enrollment  to this dose level will be 
stopped. A DLT review will occur to determine if the dose should be lowered. 
• If [ADDRESS_843489] will discontinue 
treatment. 
The decision to proceed with a RP2D or to dos e reduce will be made in a Dose Level Review 
Meeting by [CONTACT_631967] l consideration of all 
available safety and laboratory information. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 35 5.2.2. Definition of Dose Limiting Toxicities 
The following DLT criteria apply only to Ph ase 1b of the study. After completing the DLT 
period (28 d
ays), Phase 1b subjects will be  evaluated by [CONTACT_631968].  
A DLT is defined as any drug-related hematol ogic or non-hematologic toxicity Grade 3 or 
higher, with the following exceptions: 
• Grade 4 nausea, vomiting, or diarrhea or Grade 3 diarrhea defined by ≥7 stools/day 
persisting for greater than [ADDRESS_843490] supportive care 
• Grade 4 neutropenia or Grade 3 neutropenia persisting for great er than 14 days or Grade 
3 neutropenia of any duration with fever 
• For subjects with Grade 2 rash at entr y, DLT will be progression to Grade 3 AND a 
doubling of % BSA involvement 
• For subjects with Grade 3 rash at entry, DLT will be progressi on to Grade 4 OR a 
doubling of % BSA involvement 
5.2.3. Phase 2 
Following the establish
ment of the RP2D, the Phase 2 portion of the study will begin accruing 
additional subjects. Approximately 40 subjects (cumulative from both Phase 1b and Phase 2) will 
be treated with the RP2D. Subjects enrolled in the Phase [ADDRESS_843491] met the 
same inclusion/exclusion criteria as Phase 1b subjects and will be treated with the RP2D. 
Subjects continuing from Phase 1b an d subjects enrolled in Phase [ADDRESS_843492] 
discontinuation (see Section 9). 
5.3.
 Study Medication 
5.3.1.  Ibrutinib  
[IP_ADDRESS]. Formulation/Packaging/Storage  
Ibrutinib capsules are provided as a hard gela tin capsule containing 140 mg of ibrutinib. All 
form
ulation excipi[INVESTIGATOR_631941]. Refer to the 
ibrutinib Investigator's Brochure for a list of excipi[INVESTIGATOR_840].  
The ibrutinib capsules will b
e packaged in opaque high-density polyethylene plastic bottles with 
labels bearing the appropriate label text as required by [CONTACT_631969]. All 
ibrutinib capsules drug will be dispensed in child-resistant packaging.  
Refer to the Pharmacy Manual for additional guidance on study drug storage, dispensing and 
handling. Study drug labels will contain information to me et the applicable regulatory requirements. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 36 [IP_ADDRESS]. Dose and Administration 
Ibrutinib is administered orally once daily. The capsules are to be taken around the same time 
each day with 8 ounces (approxima
tely 240 mL) of  water. The capsules should be swallowed 
intact and patients should not attempt to open cap sules or dissolve them in water. The use of 
strong CYP3A inhibitors/inducers, and grapefruit and Seville oranges should be avoided for the 
duration of the study (Appendix J). 
If a dose is not taken at the scheduled time, it can be taken as soon as possible on the same day 
with a return to the normal schedule the following day. The subjects should not take extra 
capsules to make up the missed dose. The fi
rst dose will be delivered in the clinic on Day 1, after which subsequent dosing is typi[INVESTIGATOR_521033]. Ibrutinib wi ll be dispensed to subjects in bottles except Week [ADDRESS_843493] be returned to the site and drug accountability records 
(Section 12.8) updated at each visit. Returned capsul es must not be redispensed to anyone. 
[IP_ADDRESS]. Overdose 
Any dose of study drug adm
inistered in excess of that specified in this protocol is considered to 
be an overdose. Signs and symptoms of an overdose that meet any Serious Adverse Event 
criterion must be reported as a Serious Adve rse Event in the appropriate tim
e frame and 
documented as clinical sequelae to an overdose.  
There is no specific experience in the management  of ibrutinib overdose in patients. No MTD 
was reached in the Phase 1 study in whic h subjects received up to 12.5 mg/kg/day 
(1400 mg/day). Healthy subjects were exposed  up to single dose of [ADDRESS_843494] experienced reversible Grade 4 hepatic en zyme increases (AST and ALT) after a dose of 
1680 mg. Subjects who ingested more than the recommended dosage should be closely 
monitored and given appropriate supportiv e treatment . 
Refer to Section 11.4 for further information regarding AE reporting. 
[IP_ADDRESS]. Dose Modification for Adverse Reactions 
During Phase 1b, ibrutinib will be
 stopped according to DLT rules in Section 5.2.[ADDRESS_843495] ibrutinib modified or 
discontinued
 according to the guidelines in Table 1 . 
For Phase 2, the dose of ibrutinib should be modified according to the dose modificatio
n 
guidelines in Table 1  if any of the followi ng toxicities occur: 
• Grade 3 ANC (<1,000/µL) with an associated temperature ≥38.5°C 
• Grade 4 ANC (<500/µL) for more than 7 days. Refer to Section 6.1.1 for instru
ction 
regarding the use of growth factor support 
• Grade 3 thrombocytopenia (<50,000/µ L) in the presence of Grade ≥2 bleeding events 
• Grade 4 thrombocytopenia (<25,000/µL) 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 37 • Grade 3 or 4 nausea, vomiting, or diarrhea if persistent, despi[INVESTIGATOR_9025]-emetic 
and/or anti-diarrheal therapy  
• Any other Grade 4 or unmanageable Grad e 3 toxicity attributed to ibrutinib 
Table 1:  Ibrutinib Dose Modifications  
Hematologic Adverse Events  
Occurrence Action to be Taken 
First Withhold ibrutinib until recovery to an ANC ≥ 750 or platelets >25,000 with no evidence 
of Grade ≥ 2 bleeding; may restart at original dose level 
Second Withhold ibrutinib until recovery to an ANC ≥ 750 or platelets >25,000 with no evidence 
of Grade ≥ 2 bleeding; may restart at [ADDRESS_843496] Withhold ibrutinib until recovery to an ANC ≥750 or platelets >25,000 with no evidence 
of Grade ≥ 2 bleeding; may restart at [ADDRESS_843497] Withhold ibrutinib until recovery to Grade ≤1 or baseline; may restart at original dose level
Second Withhold ibrutinib until recovery to Grade ≤1 or baseline; may restart at [ADDRESS_843498] Withhold ibrutinib until recovery to Grade ≤1 or baseline; may restart at [ADDRESS_843499] will end the Treatment Phase of the study. 
 
For Grade 3 or 4 atrial fibrillation or persistent atrial fibrillation of any grade, consider the risks 
and benefits of ibrutinib treatment . If clinically indicated, the use of anticoagulants or antiplatelet 
agents may be considered for the thro mboprophylaxis of atrial fibrillation ( Section 6.2.4).  
Dose changes mu
st be recorded in the Dose  Administration eCRF. At the Investigator’s 
discretion, the dose of ibrutinib may be re-escal ated after 8 weeks of a dose reduction in the 
absence of a recurrence of the toxi city that led to the reduction. 
[IP_ADDRESS]. Dose Modification for Hepatic Impaired Subjects 
Ibrutinib is metabolized
 in the liver. For subjec ts who develop mild liver impairment while on 
study (Child-Pugh class A), the re commended dose reduction for ibru tinib/placebo is to a level 
of 280 mg daily (two capsules).  For subjects who develop mode rate liver impairment (Child-
Pugh class B), the recommended do se reduction is to a level of  140 mg daily (one capsule). 
Subjects who develop severe hepatic impairment (Child-Pugh class C) must hold study drug 
until resolved to moderate impairment (Child-Pug h class B) or better, and could be re-treated 
according to resolved hepatic conditions (ie,  140 mg or 280 mg for moderate or mild 
impairment, respectively). Monitor subjects for signs of toxicity and follow dose modification 
guidance as needed (refer to Appendix K ). 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 38 5.3.2. Management of Immunosuppression 
Participants ma
y be receiving other immunosuppressive therapi[INVESTIGATOR_014] (including extra-corporeal 
photopheresis [ECP]) in addition to glucocorticoids. In addition, due to potential drug-drug 
interactions with ibru tinib, drug levels for immunosuppressant agents such as cyclosporine, 
tacrolimus, and/or sirolimus are highly recomme nded during the clinical trial. The doses for 
these immune-suppressants should be adjusted per institutional pr actices based on the measured 
drug level. Changes in immunosupp ressive medications being used for the treatment of cGVHD 
should not be altered during the DLT window unl ess levels are documented to be at sub-
therapeutic or toxic leve ls. Concurrent use of sirolimus and a calcineurin inhibitor (tacrolimus or 
cyclosporine) are prohibited. 
5.3.3. Management of Steroids 
Systemic steroids m
ay be decrea sed at the treating physician’s discretion. The initial taper of 
steroids may begin two weeks following initiation of ibrutinib if a clinical response is seen. The 
recommendation is to not taper below 50 percent of the original  dose by [CONTACT_941] 12-week assessment 
period unless there is a documented medical  reason for steroid reduction below 50 percent 
(eg, uncontrolled diabetes, infection). A specific steroid taper schedule will not be mandated.  
Because cGVHD by [CONTACT_631970] a protean disease with clinical manifestations that wax and 
wane over time, closely spaced clinical evaluations will detect temporary exacerbations of cGVHD manifestations but may not accurately reflect the long term trajectory of a subject’s 
cGVHD and response to treatment. Therefore, in the event a participant experiences a flare of 
cGVHD, a temporary increase in steroids will be  allowed until symptoms return to baseline or 
criteria are met for progressive cGVHD. If criteria are met for progressive cGVHD, the 
participant will be scored as a treatme nt failure and removed from the study. 
Non-absorbable oral steroids will be allowed and recorded. 
5.3.4. Prophylaxis for Infections 
Prophylaxis for infections will be m
anaged according to institutional guidelines. 
6. CONCOMITANT MEDICATIONS/PROCEDURES  
Concomitant therapi[INVESTIGATOR_631942] [ADDRESS_843500]  practice (such as for emesis, diarrhea, etc.) 
are permitted. Use of neutrophil growth factors (filgrastim and pegfilgrastim) or red blood cell 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 39 growth factors (erythropoietin) is permitted pe r institutional policy and in accordance with the 
ASCO guidelines ( Smith 2006 ). Transfusions may be given in accordance with ins titutional 
policy.  
6.2. Medications to be Used with Caution 
6.2.1. CYP3A Inhibitors/Inducers 
Ibrutinib is me
tabolized primarily by [CONTACT_097]3A.  Avoid co-administration with strong CYP3A 
(eg, ketoconazole, indinavir, ne lfinavir, ritonavir, saquinavir, clarithromycin, telithromycin, 
itraconazole, and nefazadone) or mo derate CYP3A inhibitors and consider alternative agents 
with less CYP3A inhibition. If a strong CYP3A inhi bitor must be used, reduce ibrutinib dose to 
[ADDRESS_843501] be used, reduce 
ibrutinib to 140 mg for the durat ion of the inhibitor use. No dose adjustment is required in 
combination with mild inhibitors. Avoid gr apefruit and Seville oranges during ibrutinib 
treatment, as these contain mode rate inhibitors of CYP3A (see Section [IP_ADDRESS]).  
Avoid concomitant use of strong CYP3A inducer s (eg, carb
amazepi[INVESTIGATOR_050], rifampin, phenytoin, and 
St. John’s Wort). Consider alternative agents with less CYP3A induction.  
A list of common CYP3A inhibitors  or inducers is provided in Appendix J ; a comp rehensive list 
of inhibitors, inducers, and substrates may be found at 
http://medicine.iupui.edu/clinpharm/ddis/table.as px. This website is c ontinually revised and 
should be checked frequently for updates. For the most comprehensive effect of CYP3A inhi bitors or inducers on ibrutinib exposure, please 
refer to the current version of the IB. 
6.2.2. Drugs That May Have Their Plasma Co ncentrations Altered by [CONTACT_631971] a substrate of P-gl ycoprotein (P-gp), but is a mild 
inhibitor (with an IC 50 of 2.15 μ g/mL). Ibrutinib is not expected to have systemic drug-drug 
interactions with P-gp substrat es. However, it cannot be exclude d that ibrutinib could inhibit 
intestinal P-gp after a therapeutic dose. There is no clinical data available. Therefore, to avoid a 
potential interaction in the GI tract, narrow therapeutic range P-gp substrates such as digoxin, 
should be taken at least 6 hours before or afte r ibrutinib.  
6.2.3. QT Prolonging Agents 
Any me
dications known to cause QT prolongation s hould be used with caution; periodic ECG 
and electrolyte monitoring should be considered.  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843502]-surgery de pending upon the type of surgery and the risk of bleeding (see 
Section 6.4). 
Subjects requiring the in
itiation of therapeutic an ticoagulation therapy (e g, atrial fibrillation), 
(other than warfarin or a vitamin K antagoni st) during the course of  the study should have 
treatment with ibrutinib held, and ibrutinib should not be restarted until the subject is clinically 
stable. Subjects should be observed closely for signs and symptoms of bleeding. No dose reduction is required when st udy drug is restarted.  
6.3. Prohibited Concomitant Medications 
Any chemotherapy, anticancer immunotherapy, expe rime
ntal therapy, or radiotherapy are 
prohibited while the subject is re ceiving ibrutinib treatment.  
Localized, hormonal, or bone sparing treatment ma y be considered with prior approval of the 
Medical Monitor.  
The Sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapi[INVESTIGATOR_23730]. 
6.4. Guidelines for Ibrutinib Management  with Surgeries or Pr ocedures 
Ibrutinib may increase risk of bleeding with invasive procedures or surgery. The following 
guidance should be applied to th e use of ibrutinib in the peri operative period for patients who 
require surgical interventi on or an invasive procedur e while receiving ibrutinib.  
6.4.1. Minor Surgical Procedures 
For minor procedures (such as a central line  placement, needle biopsy, thoracentesis, or 
paracen
tesis) ibrutinib should be held for at least [ADDRESS_843503] 7 days after the procedure 
and restarted at the discretion of the investigator  when the surgical site is reasonably h
ealed 
without serosanguineous drainage or the need for drainage tubes.  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843504] 7 days 
after the urgent surgical procedure. 
7. STUDY EVALUATIONS   
7.1. Description of Procedures 
7.1.1. Screening/Administrative 
All screenin
g clinical and laboratory assessments must be performed within [ADDRESS_843505] dose 
of study drug (some exceptions apply). 
7.1.2. Informed Consent 
The subject must read, understand, and sign the Institu
tional Review Board/Research Ethics 
Board/Independent Ethi cs Committee (IRB/REB/IEC) approve d informed consent form (ICF) 
confirming his or her willi ngness to participate in this study before any study-specific screening 
procedures are performed. Subjects must also  grant permission to use protected health 
information per the Health Insurance Portabil ity and Accountability Act (HIPAA). In addition, 
subjects must sign all approve d ICF amendments per the site IRB/REB/IEC guidelines during 
the course of the study.  7.1.3. Confirm Eligibility 
All necessa 
ry procedures and evaluations must be performed to document that the subject meets 
all of the inclusion criteria and none of the exclusion criteria ( Section 4). Each subject must have 
an eligibility checklist completed by [CONTACT_631972]/approved by [CONTACT_37956], p
rior to enrollment. 
Clinical assessment of cGVHD must be clinically  stable or worsening for a minimum of [ADDRESS_843506]’s comp
lete history through review  of medical records and by [CONTACT_147466]. Concurrent medical signs and symptoms must be documented to 
establish baseline severities. A di sease history, including the date of  initial diagnosis and list of 
all prior cGVHD therapi[INVESTIGATOR_014], transp lant history, dates administere d, and responses and duration of 
response to these treatments,  also will be recorded.  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843507] be recorded 
as AEs in the eCRF. Laboratory abnormalitie s de
signated clinically significant by [CONTACT_631973] e events. Additional important requirements for 
adverse event and serious adverse event reporting are explained in Section 11.4. 
7.1.7. Physical Examination 
The complete physical examination will be performed at time points specified in the Schedule of 
Assessments ( Appendix A ) and will include, at a minimum, the general appearanc
e of the 
subject, height (screening only) and weight, and examination of the skin, eyes and fundi, ears, 
nose, throat, lungs, heart, abdomen, extremities,  musculoskeletal system
, nervous system, and 
lymphatic system. Please refer to Efficacy Evaluations ( Section 7.2) for the description of NIH 
cGVHD and Lee Symptom Assessments. 
On Weeks 2, 9, 13, 17, 21, and 25 visits, only a lim ited symptom-directed physical examination 
is required. Review of symptoms  should include inquiry of ocular  symp
toms; subjects should be 
referred to an ophthalmologist for a formal examination if any grade ≥ 2 symptoms are reported. 
7.1.8. Imaging 
Photographic images of the skin and oral cavities  will be captured at tim e points specified in the 
Schedule of Assessments ( Appendix A ) and sent to an indepe ndent central repository.  
7.1.9. Karnosky Performance Status 
The Karnosky Performance Status  (KPS) index is provided in Appendix C.  The performance 
status will be assessed at time points sp ecified in the Schedule of Assessm ents ( Appendix A ).  
7.1.10. Vital Signs 
Vital s
igns will include blood pressure, heart rate, respi[INVESTIGATOR_697], and body temperature and will 
be assessed at time
 points specified  in the Schedule of Assessments ( Appendix A ). 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843508] 
3 minutes. Height and we ight will also be m easured at Screening. 
7.1.11. Laboratory 
[IP_ADDRESS]. Hematology 
Hem
atology parameters performed at local labora tory will include a complete blood count: white 
blood cells, red blood cells, hemoglobin, hematocr it, platelets, neutrophils, lymphocytes, 
monocytes, eosinophils, basophils  and bands (if reported).  
[IP_ADDRESS]. Chemistry (Serum) 
Serum che
mistry parameters performed at local  laboratory will incl ude sodium, potassium, 
chloride, blood urea nitrogen (BUN), creatinine, glucose, calcium, total protein, albumin, AST, 
ALT, alkaline phosphatase, total bilirubin, la ctate dehydrogenase (LDH), phosphate, uric acid, 
magnesium and bicarbonate.  
[IP_ADDRESS]. Coagulation Studies 
Measurement of prothrombin tim
e (PT)/INR, and activated partial thromboplastin time (aPTT) 
will be performed at local laboratory at Screening.  [IP_ADDRESS]. Hepatitis Serologies 
Hepatitis serologies include hepatitis C anti body, hepatitis B surface antigen, and hep 
atitis B 
core antibody and will be evalua ted. If hepatitis B core antib ody, hepatitis B surface antigen or 
hepatitis C antibody is positive, then PCR to quantitate hepatitis B or C DNA must be performed 
and must be negative prior to randomization /enrollment. 
[IP_ADDRESS]. Donor/Host Chimerism 
Donor/host chimerism
 for the eval uation of engraftment status of the stem cell transplantation 
will be evaluated at local laboratory at time points specified in the Schedule of Assessments 
(Appendix A ).  
[IP_ADDRESS]. Immunosuppressant Level 
Measurement of
 immunosupressant levels at loca l laboratory will be obtained if clinically 
indicated.  [IP_ADDRESS]. Pregnancy Test 
Serum pregnancy tests are requir ed at Screen 
ing by [CONTACT_631974]. A urine pregnancy test will also be perform ed on Day [ADDRESS_843509] dose. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843510] may be performed 
more frequently if required by [CONTACT_631975] y authorities. 
[IP_ADDRESS]. Quantitative Serum Immunoglobulins 
Testing fo
r IgA, IgG and IgM levels will be performed at a local laboratory (time points 
specified in the Schedule of Assessments [ Appendix A ]).  
7.1.12. Diagnostics/Procedures 
[IP_ADDRESS]. ECG 
ECGs should be performe
d at the investigator’s discretion, particularly  in subjects with 
arrhythmic symptoms (eg, palpi[INVESTIGATOR_814], lightheadedness) or new onset of dyspnea. 
Subjects should be in supi[INVESTIGATOR_631943] [ADDRESS_843511]. At Screening, 12-lead ECGs will be done in triplicate (≥ 1 minute apart); the calculated QTcF 
average of the [ADDRESS_843512] be  <470 msec for eligibility.  
Any clinically significant abnorma lities noted at Screening shoul d be included in the medical 
history. 
[IP_ADDRESS]. Oxygen Saturation/Pulmonary Function Tests (PFTs) 
Subjects should be evaluated for oxygen saturation or have PF 
Ts at Screening, if not performed 
within 6 months of study entry. 
Evaluation of oxygen saturation by [CONTACT_631976] (eg, brisk walk, 
marching in place, climbing stairs). If oxygen saturation is not done at Screening, then a 
Pulmonary Function Test with a FEV1 ≥50% performed within 6 months of enrollment is 
acceptable. 
7.1.13. Pharmacokinetics/Biomarkers  
[IP_ADDRESS]. Pharmacokinetics 
Plasma
 concentrations of ibrutinib and PCI-[ZIP_CODE] will be determined using a validated analytical 
method. Other potential metabolites of ibrutinib may be explored. Refer to the Schedule of 
Assessments ( Appendix A ) and the Ph armacokinetic Sample Schedule ( Table 2 ). 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 45 Table 2:  Pharmacokinetic Sampling Schedule  
Week  Study Day 
of Study 
Week  Predose Time After Dosinga 
1h ± 15 min 2 h ± 15 min 4 h ± 30 min 6 h (± 1 h) 
[ADDRESS_843513] actual time of sample collection. 
b. Sample collected 24 hours (± 2 hours) after Day [ADDRESS_843514] art a moderate or strong CYP3A 
inhibitor while on treatm ent with ibrutinib, additional PK  blood samples for evaluation of 
ibrutinib exposure is requested at the follo wing scheduled visit after concomitant CYP3A 
inhibitor has started  and is still in use. PK sa mples will be collected at:  
• Pre-dose (If possible, sample should be obtained 22-[ADDRESS_843515] the previous day’s 
dose and before dosing on the da y of the scheduled visit)  
• 1 hour ± 15 min 
• 2 hours ± 15 min 
• 4 hours ± 30 min 
• 6 hours ± [ADDRESS_843516] not to take a dose before 
arrival at the clinic. Study drug intake will be observed by [CONTACT_96937]. The actual time (versus 
requested time) that each sample is drawn must be recorded using a 24 hour format. The same 
clock should be used for r ecording the time of dosing. 
[IP_ADDRESS]. Biomarkers and Pharmacodynamic (PD) Studies 
Sam
ples collected may be used for pharmacodynamic and biomarker assessments including BTK 
and other kinase activity and signaling, expressi on analysis, sequencing, flow cytometry and 
secreted protein analyses. Fluids  including blood collected during th e course of the study may be 
used for, but not limited to, pharmacodynamics and biomarker assessments as noted above. 
Studies will be conducted at specialty laboratorie s to determine alloreac tive B cell depletion, 
T-helper cell composition, and BTK and ITK occ upancy. Specifically, the following studies will 
be conducted: 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 46 a) Biomarker Studya: HY antigen-specific allogeneic B cell depletion in males who 
receive HCT from a female donor. 
b) Biomarker Studya: Quantification of HY IgG and IgM alloreactive antibodies males 
who receive HCT from a female donor . 
c) Pharmacodynamics Study:  BTK and ITK binding site occupation (Pharmacyclics, LLC 
[PCYC]) (Table 3). 
d) Other Studiesa: B cell depletion, flow cytometric analysis of T-helper cell composition, 
T and B cell cytokine analysis, and phosphoflow analysis of CD4+ T-cell ITK blockade. 
a. Performed at designated central laboratory, refer to Laboratory Manual. 
Table 3: PD (BTK and ITK Occupancy) Sampling Schedule (collection for PCYC) 
Week  Study Day  
of Study Week  Predosea Time After Dosinga 
4 h ± [ADDRESS_843517] actual time of sample collection. 
b. Sample collected 24 hours (± 2 hours) after Day 1 dose and prior to dosing on the study day. 
 
After samples are collected, samples will be proc essed onsite before shippi[INVESTIGATOR_631944]/analysis. Please refer to La boratory Manual for instructions. 
[IP_ADDRESS]. T/B/NK Counts 
The blood sample(s) for T/B/NK cell count (CD3+, CD4+, CD8+, CD19+, CD16/56+) must be 
collected at the time points specified in the Schedule of Assessments (Appendix A ) and the 
T/B/NK Sa
mpling Schedule ( Table 4). 
Table 4: T/B/NK Sampling Sche dule (collection for PCYC)  
Week  Study Day 
of Study Week  Predosea Time After Dosinga 
4 h ± [ADDRESS_843518] actual time of sample collection. 
b. Sample collected 24 hours (± 2 hours) after Day 1 dose and prior to dosing on the study day. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 47 After samples are collected, samples will be proc essed onsite before shippi[INVESTIGATOR_631944]/analysis. Please refer to la boratory manual for instructions.  
7.2. Efficacy Evaluations 
7.2.1. NIH Response Criteria (see Appendix F  and Appendix G ) 
All subjects in the study w ill have their response assesse d using the NIH cGVHD Response 
assessm ent (Pavletic 2006; Measurement of Therapeutic Response, ASBMT Web site ) at 
baseline, at week 5, and after every 12 weeks of therapy. Response will be determined by [CONTACT_70135]: 
1. Complete Response – Complete resolution of all reversible manifestations of cGVHD. 
Irreversible m
anifestations will be de
fined by [CONTACT_12813] (Pavletic 2006) 
(eg, ocular xerosis, esophageal stri cture, and bronchiolitis obliterans). 
2. Partial Response – At least a 25% absolute or 50% relative change (whichever is greater) 
when comparing start and end measurements in one cGVHD domain without worsening in 
the other domains ( Appendix H ). 
3. Stable Disease – No worsening in baseline cGVHD manifestations. 
4. Progressive Disease – Worseni ng in any one cGVHD do
main by [CONTACT_631977] 25% from baseline unless baseline values are within 25% of the scale used to score cGVHD. In addition, a new cGVHD manifestation also counts as progression ( Appendix H ). 
7.2.2. Lee cGVHD Symptom Scale  
All subjects in the study will complete the Lee Symptom scale ( Appendix E ) after every 
12 weeks of study treatme
nt. A change in >7 points on the Lee cGVHD Symptom Scale will be 
considered clinically significant and rela tes to improvement in quality of life ( Lee 2006 ). 
7.2.3.  Failure Free Survival 
Failure free survival will be de fined as no death, no relapse of  underlying malignancy, and no 
new immunosuppressive therapy. FFS will be assesse d every 6 months starting with beginning of
 
therapy. FFS with corticosteroid requirem
ents at 6 months and 12 months on therapy will be 
assessed as described in Inamato et al. ( Inamato 2013 ). 
7.3. Sample Collection and Handling 
The actual dates and times of samp
le collection must be recorded in source documents for 
transcription to the eCRF or laboratory requisiti on form. Refer to the Schedule of Assessments 
(Appendix A ) for the timing and frequency of all sample collections. 
Instructions for the collection, handling, and shipment of samp les are found in the Laboratory 
Manual. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 48 8. STUDY PROCEDURES   
Each of the phases (1b or 2) in this study is divided into 3 sub-phases: Screening Phase, a 
Treatment Phase, and a Follow-up Phase. The Schedule of Assessments ( Appendix A ) 
summarizes the frequency and timing of efficacy, PK, PD, biom
arker, and safety measurements 
applicable to this study. All subjects enrolled  will undergo the same study procedures throughout 
the study unless otherwise noted. 
Details for each part are presented below a nd can be found on the Schedule of Assessments 
(Appendix A ). 
8.1. Screening Phase 
The Screening period can occur up to [ADDRESS_843519] read, understand, and sign the IRB/REB/IEC approved ICF before any study-specific 
screening procedures are perfor med. Standard of care follow-up pe r institutional practices do not 
require prior consent (eg, routin e laboratory testing). All study tests and procedures should be 
performed at the study center at which the subjec t was enrolled and will be  receiving treatment. 
After signing the ICF, screening, and being deemed eligible for entry, subject s will be enrolled in 
the study after review and approval of screeni ng inclusion/exclusion records by [CONTACT_526950].  
8.1.1. Screening Visit 
The fo
llowing procedures will be performed at the Screening Visit within [ADDRESS_843520] 
dose of study drug and randomization unless otherwise noted:  
• Obtain signed, written informed consent 
• Medical history including demographic information 
• Collection of tran splant history 
• Evaluation of KPS performance status 
• Complete physical exam includi ng height and weight (may use prior height measurement 
if available in source documents). 
• Record adverse events since signing the ICF 
• Record concomitant medication history including over-the-counter drugs, vitamins and 
herbs 
• cGVHD assessment (eg, NIH assessments [ Appendix F  and Appendix G ])  
• Lee cGVHD Sym
ptom Scale ( Appendix E ) 
• Obtain vital signs (including blood pressu re, heart rate, resp iratory rate, and body 
temp
erature) after the subject has rested in the sitting position for ≥3 minutesObtain 
blood specimens for the following laboratory tests: 
o Hematology 
o Serum chemistry 
o Coagulation studies: PT/INR, aPTT 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 49 o Hepatitis serologies/PCR 
o Quantitative serum immunoglobulins (IgA, IgG, and IgM) 
• Donor/host Chimerism testing 
• T/B/NK sampling for PCYC 
• Perform oxygen saturation and/or PFT (if O 2 not assessed within 6 months of study entry) 
• Obtain triplicate 12-lead ECG (≥ 1 minute apart) after the subj ect has been in a supi[INVESTIGATOR_521061] 10 minutes 
• Immunosuppressant level – if applicable 
• Obtain serum pregnancy test for wo men of childbearing potential only 
• Complete enrollment-eligibility  checklist and submit to Sponsor for review and approval 
prior to enrollment  
8.2. Treatment Phase 
Following completion of the Screening Visit and once eligibility has been conf
irmed, subjects 
are enrolled. Enrollment should occu r as close to the time of the expected first dose as possible, 
ie, not more than [ADDRESS_843521] dose with study drug.  
During the treatment/follow-up period, DLT assessment will occur over a 28-day period. DLTs 
are defined in Section 5.2.2. Local labs will be used to guide all dosing-related decisions .  
Week 1 Day 1  
Predose 
• Complete physical exam  including weight.  
• Vital signs and performance status (KPS) 
• cGVHD assessment per NIH ( Appendix F  and Appendix G ). This assessment must be a 
minimum of [ADDRESS_843522]'
s cGVHD is 
worsening. If the subject's cGVHD is clinically improved from the prior response 
assessment, then the first dose must be delayed and subject will need to be re-assessed at 
least [ADDRESS_843523] the Medical 
Monitor for any questions related to eligibility. 
• Lee cGVHD Symptom Scale ( Appendix E)  
• Photographic imaging of cGVHD  
• Hematology 
• Serum chemistry 
• Urine pregnancy test for wome n of c
hildbearing potential 
• Review of baseline adverse events and conc omitant medications (including corticosteroid 
requirements) 
• Review of inclusion and exclus ion criteria to confirm subject eligibility prior to first 
dosing 
• Pharmacokinetic sampling (pre-dose) 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 50 • Pharmacodynamic sampling for PCYC (pre-dose) 
• T/B/NK sampling for PCYC (pre-dose) 
• Biomarkers sampling  
• Immunosuppressant level – if applicable  
Post Dose 
• Administer ibrutinib at speci fied dose level, and then dispense remaining amount to 
subject for at-home dosing  
• Provide drug diary and dosing instructions to subject  
• Pharmacokinetic sampling for PCYC  at 1, 2, 4, and [ADDRESS_843524]-dose 
• Pharmacodynamic sampling for PCYC ([ADDRESS_843525] dose administration) 
• T/B/NK sampling for PCYC ([ADDRESS_843526] dose administration) 
• Review adverse events   
Week 1 Day 2  
Predose  
• a.Pharmacokinetic sampling for PCYC (pre- dose before Day 2 drug administration) 
• a.Pharmacodynamic sampling for PCYC (pre-dose before Day 2 drug administration) 
• a.T/B/NK sampling (pre-dose) 
a. Within [ADDRESS_843527] ibrutinib dose.  
Week 2  
Predose 
• Symptom-directed physical examination 
• Hematology 
• Serum chemistry 
• Vital signs 
• Immunosuppressant level – if applicable 
• Review adverse events and concomitant medications (including corticosteroid 
requirements) 
• Pharmacokinetic sampling for PCYC (pre-dose) 
• Pharmacodynamic sampling for PCYC (pre-dose) 
• T/B/NK sampling for PCYC (pre-dose before Day 2 drug administration) 
 
During and Post Dose 
• Administer ibrutinib at  specified dose level 
• Pharmacokinetic sampling for PCYC  at 1, 2, 4, and [ADDRESS_843528]-dose 
• Pharmacodynamic sampling for PCYC ([ADDRESS_843529] dose administration) 
• T/B/NK sampling for PCYC (4 hours after drug administration) 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 51 Week 5, 9, 13, 17, 21, 25 (± 3 days)  
Predose 
• DLT assessment period ends (Phase 1b Week 5 only) 
• Symptom-directed physical examination 
• Vital signs and performance status (KPS) 
• Photographic imaging of cGVHD (Weeks 5, 13 and 25) 
• Hematology 
• Serum chemistry 
• cGVHD assessment per NIH (Weeks 5, 13 and 25) ( Appendix F  and Appendix G ) 
• Lee cGVHD Symptom Scale (Weeks 5, 13 and 25) ( Appendix E) 
• Donor/host chimerism testing (Weeks 13 and 25) 
• Quantitative serum immunoglobulins (IgA, IgG, and IgM) (Weeks 13 and 25) 
•
 Biomarker sampling (Weeks 5, 12 and 25) 
• Pharmacodynamic sa
mpling for PCYC (pre-dose on Weeks 9 and 13) 
• T/B/NK sampling for PCYC (pre-dose on Weeks 9 and 13) 
• Immunosuppressant level – if applicable 
• Review returned subject dosing diary 
• Review adverse events and concomitant medications (including corticosteroid 
requirements)  
Post Dose 
• Administer ibrutinib at speci fied dose level, and then dispense remaining amount to 
subject  
• Pharmacodynamic sample collection (4 hours after drug administration on Weeks 9 and 
13) 
• T/B/NK sampling for PCYC (4 hours after drug administration on Weeks 9 and 13)  
Week 37 and every 12 weeks thereafter   
Predose 
• Complete physical examination 
• Vital signs and performance status (KPS) 
• Photographic imaging of cGVHD  
• Hematology 
• Serum chemistry 
• cGVHD assessment per NIH ( Appendix F  and Appendix G ) 
• Lee cGVHD Symptom Scale ( Appendix E)  
• Donor/host chimerism testing 
• Quantitative serum immunoglobulins (IgA, IgG, and IgM) 
• Biomarker sampling (Weeks 37 and 49) 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 52 • Immunosuppressant level – if applicable 
• Review returned subject dosing diary 
• Review adverse events and concomitant medications (including corticosteroid 
requirements)  
Post Dose 
• Administer ibrutinib at speci fied dose level, and then dispense remaining amount to 
subject  
8.2.1. Progressive Disease Visit 
Progressive Disease vis it should be performe
d at any time during the study, if based on clinical 
and/or laboratory evalua tion, the Investigator suspects progre ssive disease, or if the subject 
discontinues treatment for any other reason. If pos sible, the visit should be performed within 
[ADDRESS_843530]’s previous dose.  
• Complete physical examination 
• Vital signs and performance status (KPS) 
• Hematology 
• Serum chemistry 
• Donor/host chimerism testing 
• Immunosuppressant level – if applicable 
• cGVHD NIH Form assessment ( Appendix F  and Appendix G ) 
• Lee cGVHD Sym
ptom  Scale  (Appendix E ) 
• Photographic imaging of cGVHD  
•
 Quantitative serum immunoglobulins (IgA, IgG, and IgM) 
• Review adverse events and concomitant medications (including corticosteroid requirements) 
• Review returned subject dosing diary 
• Final drug accountability 
8.2.2. End-of-Treatment Visit 
An End-of-Treatme
nt visit shoul d occur 30 days (± 7 days) from the last dose of study drug or 
prior to the start of a new cGVHD treatment. If  the subject starts a new cGVHD treatment less 
than 7 days after the Progressive Disease visit, only those procedures not conducted at the 
Progressive Disease visit s hould be performed at the E nd-of-Treatment visit.  
The following procedures will be performed at the End-of-Treatment visit: 
• Complete physical examination 
• Vital signs and performance status (KPS) 
• Hematology 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 53 • Serum chemistry 
• Donor/host chimerism testing Lee cGVHD Symptom Scale ( Appendix E) 
• cGVHD NIH Form assessment ( Appendix F  and Appendix G ) 
• Photographic imaging of cGVHD  
• Immunosuppressant level – if applicable 
• Quantitative serum immunoglobulins (IgA, IgG, and IgM) 
• Review returned subject dosing diary 
• Review adverse events and concomitant 
medications (including corticosteroid 
requirements and any new cGVH D treatm
ent if applicable) 
• Final drug accountability 
• Biomarker sampling 
8.3. Follow-up Phase 
Once a subject has completed the End-of-Treatme nt Visit they will enter the Follow-Up Phase 
(Visits every 12 Weeks).  
8.3.1. Response Follow-up 
Subjects who discontinue the study for reasons othe r than progressive dise ase will be followed 
every 12 weeks (±7 days) by [CONTACT_631978]. During this period, the 
following procedures will be performed: 
• Symp
tom-directed physical examination 
• Vital signs and performance status (KPS) 
• Hema
tology 
• Serum chemistry 
• Donor/host chimerism testingcGVHD NIH Form assessment ( Appendix F  and 
Appendix G ) 
• Lee cGVHD Symptom Scale ( Appendix E ) 
• Photographic imaging of cGVHD  
• Review corticosteroid requirements a nd any new cGVHD treatment if applicable  
8.3.2. Long-Term Follow-up 
Once subjects progress (for subjects who have not withdrawn consent), they will be contact[CONTACT_315128] 3 months (±14 days) by [CONTACT_631979]. Subjects 
will be con
tacted until death, subject withdrawal, lost to follow-up, or study termination by [CONTACT_429], whichever occurs first. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843531] to follow up, or has not withdrawn consent be fore the end of study.  
9.2.
 Withdrawal from Study Treatment 
Study treatment will be discontinued in the ev
ent of any of the following events: 
• cGVHD progression (see definition in Section 7.2.1) 
• Unacceptabl
e toxicity: an interc urrent illness or AE that prevents further ibrutinib 
administration. 
• Noncompliance with study medication. 
• Investigator’s decision (such as chronic noncom pliance, significant protocol deviation, or 
best interest of the subject) 
• Withdrawal of consent for treatment by [CONTACT_1130] 
• Malignancy progression/relapse. 
• Subject’s condition no longer requires study treatment. 
• Subject becomes pregnant 
• Study termination by [CONTACT_2728] 
• Death 
All subjects, regardless of reason for disc ontinuation of study treatment will undergo an 
End-of-Treatment Visit and be follo wed for progression and survival.  
9.3. Withdrawal from Study 
Withdrawal from
 study (including all follow-up) will occur under the following circumstances: 
• Withdrawal of consent for follow-up observation by [CONTACT_423] 
• Lost to follow-up 
• Study termination by [CONTACT_2728] 
• Death 
If a subject is lost to foll ow-up, every reasonable effort should be made by [CONTACT_393070] t. The measures taken to fo llow up should be documented. 
When a subject withdraws before completing the study, the following information should be 
documented in the source documents: 
• Reason for withdrawal; 
• Whether the subject withdraws consent (ie, w ithdraws consent to treatment and all further 
contact) or withdraws consent to  treatment but agrees to part icipate in follow-up visits.  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 55 10. STATISTICAL METHODS AND ANALYSIS  
Statistical analysis will be done by [CONTACT_183974]. A general 
description of the statistical methods to be used to analyze the efficacy and safety data is outlined 
below. Specific details will be provided in the Statistical Analysis Plan (SAP).  
The primary analysis for all efficacy and safety  endpoints will be conducted at approximately 
[ADDRESS_843532]’s first dose of study drug. 
10.1. Subject Information 
The following definitions will be used for the safety and efficacy analysis, respectively: 
• Safety population: All enrolled subjects who receive at least one dose of study drug.  
• Efficacy population:  All enrolled subjects who receive at least one RP2D of study drug. 
Additional analysis populations, which mi
ght be used for sensitivity analyses and biomarker 
studies, are defined in the SAP. 
10.2. Endpoints  
10.2.1. Primary Endpoints 
Phase 1b:  
Safety and Tolerability 
Drug toxicity will be described and graded ac cording to CTCAE v. 4.[ADDRESS_843533] 28 days for Phase 1b subjects will b
e described and graded 
according to CTCAE v. 4.03 criteria and presente d in tabulated form. This will also be 
performed for subjects enrolled in  the Phase 2 portion of the study.  
Phase 2:  
The primary efficacy endpoint is the best overall cGVHD response ra te. Best overall cGVHD 
response rate is defined the proportion of subject s who achieve a NIH-defined complete response 
or partial response.  
Please refer to Section 7.2.1 for the definition of overall cGVHD response. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 56 10.2.2. Secondary Efficacy Endpoints 
[IP_ADDRESS]. Rate of Sustained Response for at Least [ADDRESS_843534] 5 months.  
[IP_ADDRESS]. Duration of Response (DOR) 
Duration of response is defined as  the interval between the date  of initial documentation of a 
response, and the date of first docum
ented evidence of progressive diseas e, death, or date of 
censoring if applicable, for res ponders only. Percentage of subjec ts with sustained response and 
its 95% confidence interval will be calculat ed using normal approximation to the binomial 
distribution. Subjects who stop the study dr ug and start new GVHD treatment before 
documentation of disease progression will be censored on the date of the last adequate disease 
assessment that is on or before the start date  of new GVHD therapy. Responders are subjects 
who achieve a NIH-defined complete res ponse or partial response during the study. 
Non-responders will be exclude d from the analysis for DOR. 
[IP_ADDRESS]. Corticosteroid Requirement Changes Over Time 
Corticostero
id requirement will be monitored cr oss the study. The decrease of corticosteroid 
need will be viewed as the benefit of the ibrutinib.  
[IP_ADDRESS]. Change in cGVHD Symptom Scale 
Subject reported im
provement in symptom burden. The symptom burden will be measured 
according to the Lee cGVHD Symptom Scale. A change in >7 points on the Lee cGVHD 
Symptom Scale will be considered significant an d relates to improvement in quality of life 
(Lee 2006 ). 
10.2.3. Safety Endpoints 
Safety asses
sments will consist of monitoring and recording AEs and SAEs; measurements of 
protocol-specified hematology, clinical chemistr y, urinalysis, and othe r laboratory variables; 
measurement of protocol-specified tests that are deemed critical to the safety evaluation of the 
study drug. 
10.2.4. Exploratory Endpoints 
[IP_ADDRESS]. Photographic Changes in Skin and Mucocutaneous Manifestations. 
Skin and mu
cocutaneous manifestations will be monitored across the study. The decrease of area 
with skin and mucocutaneous manifestations will be view as the benefit of the ibrutinib.  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 57 [IP_ADDRESS]. Pharmacokinetic Analysis  
Plasma
 concentrations of ibrutinib and me tabolite PCI-[ZIP_CODE] will be determined using a 
validated analytical method. Other potential metabolites of ibrutinib may be explored. 
Bioanalytical data from this study will be used  in noncompartmental PK analysis and also may 
be combined with data from other studies perfor med with ibrutinib in subjects with hematologic 
malignancies as part of a population PK analysis  using nonlinear mixed effects models. For the 
population PK analysis, covariates that could potentially  correlate with plas ma PK parameters 
will be evaluated. The results of the population PK analyses (if perf ormed) will be presented in a 
separate report. 
[IP_ADDRESS]. Biomarker and Pharmacodynamic Studies 
Pharmacodynam
ic studies will be conducted to determine alloreactive B cell depletion, T-helper 
cell composition, BTK occupancy and ITK blockade. Specifically, the following PD studies will 
be conducted: 
• HY antigen-specific allogeneic B cell depleti on in males who receive HCT from a female 
donor. 
• Quantification of HY IgG and IgM alloreactiv e antibodies males who receive HCT from 
a female donor. 
• BTK and ITK binding site occupation (PCYC). 
• B cell depletion, flow cytometric analysis  of T-helper cell composition, T and B cell 
cytokine analysis, and phosphoflow anal ysis of CD4+ T-cell ITK blockade. 
[IP_ADDRESS]. Failure Free Survival  
Failure free survival is defined as no death, no relapse of ma
lignancy, and no new 
immunosuppressive therapy for GVHD. 
10.3. Sample Size Determination 
With a sa
mple size of [ADDRESS_843535] overall cGVHD response rate of 
approximately 50%, it is expected to have at least 90% power to show the efficacious treatment 
effect (the lower bound of 95% CI  of the response rate >0.25). 
10.4. Efficacy Analysis  
Best overall cGVHD response rate a nd its 95% confidence interval will be calculated with the 
exact test for binom ial distribution.  
The secondary efficacy endpoint rate of sustai ned response for at least [ADDRESS_843536] overall cGVHD response rate.  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 58 The distribution (median and Kaplan-Meier curves) and estimates of DOR will be provided 
using Kaplan-Meier estimates for responders. 
Other secondary endpoints, such as on corticoste roid requirement changes over time, change in 
symptom burden measured by [CONTACT_631980].  
Exploratory endpoints will be will be summarized by [CONTACT_9086]. 
10.5. Safety Analysis 
 The safety variables to be analyzed include adverse events, clinical laboratory test results 
(hem
atology and chemistry), and other safety measurements. They will be summarized by 
[CONTACT_9086]. No formal statistical testing is planned.  
Exposure to ibrutinib first dose and reasons for discontinuation from study treatment will be 
tabulated. 
Adverse Events 
Adverse event parameters to be evaluated are the type, incidence, a nd intensity of adverse 
events; the relationship of adverse events to ibrutinib; and the action taken with respect to 
ibrutinib treatment due to adverse events. 
The verbatim terms used in the eCRF will be co ded using the Medical Dictionary for Regulatory 
Activities (MedDRA).  Treatment-emergent adverse events are those adve rse events occurring af ter the first dose of 
study drugs and within [ADDRESS_843537]  dose of study drug; any adverse event that is 
considered study drug-related regard less of the start date of the ev ent; or any adverse event that 
is present at baseline but wors ens after the first administration of study drug in severity or is 
subsequently considered drug-related by [CONTACT_57748]. All treatment-emergent adverse events 
will be included in the analysis.  
For each adverse event, the percentage of subject s who experience at least 1 occurrence of the 
given event will be summarized. The number and percent of subjects with treatment-emergent 
adverse events will be summarized according to intensity (NCI CTCAE v. 4.03) and drug relationship as well as categor ized by [CONTACT_6657]. Summaries, 
listings, datasets, or subject na rratives may be provided, as appropriate, for those subjects who 
die, who discontinue treatment due to an adverse event, or who experience a severe or a serious 
adverse event. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843538] Op erating Procedures in 
conformity with regulatory requi rements worldwide to ensure appropriate reporting of safety 
information; all clinical studies conducted by [CONTACT_3433] e Sponsor or its affiliate s will be conducted in 
accordance with those procedures. 
11.1. Definitions  
11.1.1. Adverse Events 
An AE is any untoward me
dical occurrence in a subject administered a pharmaceutical product 
and which does not necessarily have a causal re lationship with this treatment. An AE can 
therefore be any unfavorable and unintended si gn (including a clinical ly significant abnormal 
laboratory finding, for example), symptom, or diseas e temporally associated  with the use of an 
investigational study drug, whether or not considered related to the study drug ( ICH-E2A, 1995 ). 
For the purpo
ses of this clinical study, AEs incl ude events which are either new or represent 
detectable exacerbations of  pre-existing conditions. 
The term “disease progression” should not be report ed as an adverse event term. As an example, 
"worsening of underlying disease" or the clinical diagnosis that  is associated with disease 
progression should be reported. 
Adverse events may include, but are not limited to: 
• Subjective or objective symptoms provide d by [CONTACT_5363]/or observed by [CONTACT_631981]. 
• Any AEs experienced by [CONTACT_631982] l study procedures. 
• AEs not previously observed in the patient that emerge during the pr otocol-specified AE 
reporting period, including signs or symptoms associated with cGVHD that were not 
present before the AE reporting period  
• Complications that occur as a result of pr otocol-mandated interventions (eg, invasive 
procedures such as biopsies). 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 60 The following are NOT considered AEs: 
• Pre-existing condition: A pre-existing condition (docum ented on the medical history 
CRF) is not considered an AE unless the seve rity, frequency, or ch aracter of the event 
worsens during the study period. 
• Pre-planned or elective hospi[INVESTIGATOR_059]:  A hospi[INVESTIGATOR_14147], but rather a therapeutic intervention. 
However, if during the pre-planned hospi[INVESTIGATOR_14148], which prolongs the 
hospi[INVESTIGATOR_631945] a, the event will be considered an SAE. 
Surgeries or interventions that were under consideration, but not performed before enrollment in the study, will not be consider ed serious if they are performed after 
enrollment in the study for a condition that has not changed from its baseline level. 
Elective hospi[INVESTIGATOR_393024] r social reasons, solely for the administration of 
chemotherapy, or due to long travel  distances are also not SAEs. 
• Diagnostic Testing and Procedures:  Testing and procedures s hould not to be reported 
as AEs or SAEs, but rather the cause for the test or procedure should be reported. 
11.1.2. Serious Adverse Events 
A serious adverse event based on ICH and EU Gu idelines on Pharm
acovigilance for Medicinal 
Products for Human Use is any untoward medical occurrence that at any dose: 
• Results in death (ie, the AE act ually causes or leads to death). 
• Is life-threatening. Life-threatening is defined as  an AE in which the patient was at risk of 
death at the time of the event. It does not refer to an event which hypothetically might 
have caused death if it were more severe. If either the Investig ator or the Sponsor 
believes that an AE meets the definition of life-threatening, it will be considered 
life-threatening. 
• Requires in-patient hospi[INVESTIGATOR_1838] >24 hours or prolongation of existing hospi[INVESTIGATOR_059]. 
• Results in persistent or significant disability/in capacity (ie, the AE results in substantial 
disruption of the patient’s ability to conduct normal life functions). 
• Is a congenital anomaly/birth defect. 
• Is an important medical event that may not result in death, be immediately 
life-threatening or require hospi[INVESTIGATOR_059], but may be considered an SAE when, 
based upon appropriate medical j udgment, the event may jeopardize the patient or patient 
may require intervention to prevent one of the other outcomes listed in this definition. 
Examples of such events are intensive treatm ent in an emergency department or at home 
for allergic bronchospasm, blood dyscrasias,  or convulsion that does not result in 
hospi[INVESTIGATOR_059]; or development of  drug dependency or drug abuse. 
Given that the Investigator’s perspective may be informed by [CONTACT_393085], 
and the Sponsor is likely to have broader knowle dge of the drug and its effects to inform its 
evaluation of the significance of the event, if eith er the Sponsor or the Investigator believes that 
the event is serious, the event will be considered serious. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 61 11.1.3. Severity Criteria (Grade 1-5) 
Definitions found in the Common Term
inology Cr iteria for Adverse Events version 4.0 
(CTCAE v. 4.03) will be  used for grading the severity (intensity) of AEs. The CTCAE v. 
4.03displays Grades 1 through 5 with unique clinical descriptions of severity for each referenced 
AE. Should a patient experience any AE not lis ted in the CTCAE v. 4.03, the following grading 
system should be used to assess severity: 
• Grade 1 (Mild AE) – experiences which are usually transient, requiring no special 
treatment, and not interfering with the patient’s daily activities 
• Grade 2 (Moderate AE) – experiences which introduce some level of inconvenience or 
concern to the patient, and which may inte rfere with daily activ ities, but are usually 
ameliorated by [CONTACT_14212] 
• Grade 3 (Severe AE) – experiences which are unacceptable or intolerable, significantly 
interrupt the patient’s usual daily activity, and require sy stemic drug therapy or other 
treatment 
• Grade 4 (Life-threatening or di sabling AE) – experiences which cause the patient to be in 
imminent danger of death 
• Grade 5 (Death related to AE) – experi ences which result in patient death 
11.1.4. Causality (Attribution)  
The Investigator is to a
ssess the causal relation (ie, whether there is a reasonable possibility that 
the study drug caused the event) using the following definitions: 
Not Related: Another cause of the AE is more plausible; a temporal sequence 
cannot be established with the onset of the AE and 
administration of the investig ational product; or, a causal 
relationship is considered biologically implausible. 
Unlikely: The current knowledge or inform ation about the AE indicates 
that a relationship to the inve stigational product is unlikely. 
Possibly Related: There is a clinically plausibl e time sequence between onset of 
the AE and administration of the investigational product, but the 
AE could also be attributed to concurrent or underlying disease, 
or the use of other drugs or procedures. Possibly related should 
be used when the investigati onal product is one of several 
biologically plausible AE causes. 
Related: The AE is clearly related to us e of the investigational product. 
11.2. Unexpected Adverse Events 
An “unexpected” AE is an AE that is not listed in the Investigator's Brochure/package insert or is 
not listed at the specificity or severity that ha s been observed. For example, hepatic necrosis 
would be “unexpected” (by [CONTACT_393086]
) if the Investigator 's Brochure referred only 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 62 to elevated hepatic enzymes or hepatitis. Similarly, cerebral thromboembolism and cerebral 
vasculitis would be “unexpected” (by [CONTACT_145178]) if the Investigator's 
Brochure/package insert listed only cerebral vascular accidents. "U nexpected" also refers to AEs 
that are mentioned in the Investigator's Brochur e as occurring with a class of drugs or as 
anticipated from the pharmacological properties of  the drug, but are not specifically mentioned 
as occurring with the study drug under investigation. 
11.3. Special Reporting Situations 
Special reporting situa tion on a Sponsor study ma
y require ex pedited reporting and/or safety 
evaluation include, but are not limited to: 
• Overdose of any study drug 
• Suspected abuse/misuse of a study drug 
• Inadvertent or accidenta l exposure to a study drug 
• Medication error involving a product (with or without subject/patient exposure to the 
study drug, eg, name [CONTACT_2976]) 
Occurrence of any special reporting situations sh ould be recorded in th e eCRF. If any special 
reporting situation meets the criteria of an adve rse event, it should be recorded on the adverse 
events eCRF. If the adverse event is consider ed serious, it should be recorded on the adverse 
events eCRF as serious and should be reported on the Serious Adverse Event Report Form. The 
SAE Report Form should be sent via email or fax to Pharmacyclics Drug Safety or designee 
within [ADDRESS_843539]’s medical record and on the Adverse Event CRF and, when applicable, on 
the Serious Adverse Event Report Form. 
Each recorded adverse event or serious adverse ev ent will be described by  [CONTACT_13662] (ie, start 
and end dates), severity, regulator y seriousness criteria (if applicab le), suspected relationship to 
the investigationa l product, and any actions taken. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843540] dose of study drug should also be 
reported if considered related to study drug. Resolution information after 30 days should be 
provided.  
Progressive disease should NOT be reported as an event term, but instead symptoms/clinical 
signs of disease progression may be reported. All adverse events, regardless of seriousness, seve rity, or presumed relationship to study drug, 
must be recorded using medical terminology in the source document. All records will need to 
capture the details of the durati on and the severity of each epi[INVESTIGATOR_1865] , the action taken with respect 
to the study drug, investigator’s evaluation of its relationship to the study drug, and the event 
outcome. Whenever possible, dia gnoses should be given when signs  and symptoms are due to a 
common etiology (eg, cough, runny nose, sneezing, so re throat, and head congestion should be 
reported as "upper respi[INVESTIGATOR_631946]"). Investigators must r ecord in the CRF their opi[INVESTIGATOR_393025] t to study therapy. All measures required for 
adverse event management must be recorded in  the source document and reported according to 
Sponsor instructions. 
All deaths should be reported with the primary cause of death as the AE term, as death is 
typi[INVESTIGATOR_36069], not the ev ent itself. The primary cause of death on the 
autopsy report should be the term reported. Auto psy and postmortem reports must be forwarded 
to the Sponsor, or designee, as outlined above. If a death occurs within [ADDRESS_843541] be reported to 
the Sponsor as a serious adverse event.  
11.4.3. Expediting Reporting Requirements for Serious Adverse Events 
All seri
ous adverse events (initial and follow-up information) will be reported on the Serious 
Adverse Event Report Form and sent via email or fax to Pharmacyclics Drug Safety, or designee, 
within [ADDRESS_843542] follow-
up and other additional information from the Inve stigator (eg, hospi[INVESTIGATOR_393026]/discharge notes 
and laboratory results). The cont act information (phone, email and fax) for Pharmacyclics Drug 
Safety can be found on the Serious Advers e Event Report Form and instructions. 
All serious adverse events that have not reso lved by [CONTACT_2054], or that have not 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843543]'s pa rticipation in the study, must be followed until 
any of the following occurs: 
• The event resolves 
• The event stabilizes 
• The event returns to baseline, if a baseline value/status is available 
• The event can be attributed to agents other than the study drug  or to factors unrelated to 
study conduct 
• It becomes unlikely that any additional info rmation can be obtained  (subject or health 
care practitioner refusal to provide additional information, lost to follow up after 
demonstration of due dilige nce with follow-up efforts) 
The Sponsor assumes responsibility for appropriate reporting of AEs to th e regulatory authorities 
and governing bodies according to the local regulations.  
The investigator (or Sponsor where required) mu st report these events to the appropriate 
Independent Ethics Committee/Institutional Review  Board (IEC/IRB) that approved the protocol 
unless otherwise required and documented by [CONTACT_6179]/IRB.  
11.4.4. Adverse Events of Special Interest (AESI) 
Specific adverse events, or groups of adverse events , will b
e followed as part of standard safety 
monitoring activities by [CONTACT_3433] e Sponsor. These events (regardless of seriousness) should be reported 
on the Serious Adverse Event Report Form and se nt via email or fax to Pharmacyclics Drug 
Safety, or designee, within 24 hours of awareness.  [IP_ADDRESS]. Major Hemorrhage 
Major hemorrhage is defi 
ned as any of the following:  
• Any treatment-emergent hemorrhagic AEs of Grade 3 or higher*. Any treatment-
emergent serious adverse events of bleeding of any grade 
• Any treatment-emergent central  nervous system hemorrhage/hematoma of any grade 
*All hemorrhagic events requiring transfusion of red blood cells should be reported as Grade [ADDRESS_843544], consent to provide follow-up 
information regarding the outcome of the pregnancy and the health of the in fant until 30 days old 
will be requested. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843545] dose of study drug. Any female subjects receiving study drug(s) who become 
pregnant must immediately discontinue study drug. The Investigator should counsel the subject, 
discussing any risks of conti nuing the pregnancy and any possible effects on the fetus.  
Although pregnancy itself is not regarded as an  adverse event, the outcome will need to be 
documented. Any pregnancy occurring in a subject or subject’s partner from the time of consent 
to [ADDRESS_843546] 
be recorded on the Pregnancy Report Form Part I and sent via email or fax to Pharmacyclics 
Drug Safety, or designee, within 24 hours of l earning of the event. A ll pregnancies will be 
followed for outcome, which is defined as elective termination of the pregnancy, miscarriage, or 
delivery of the fetus. For pregnancies with an outcome of live birth, the newborn infant will be 
followed until 30 days old by [CONTACT_631983]. Any congenital 
anomaly/birth defect noted in the infant mu st be reported as a serious adverse event. 
11.4.6. Other Malignancies 
In addition to all routine AE reporting, all new malignant tumors including solid tum
ors, skin 
malignancies and hematologic malignancies are to be reported for the dura tion of study treatment 
and during any protocol-specifi ed follow-up periods includin g post-progression follow-up for 
overall survival. If observed, ente r data in the corresponding eCRF. 
12. STUDY ADMINISTRATION AND INVESTIGATOR OBLIGATIONS   
12.1. Regulatory and Ethical Compliance 
This clinical study was de
signed and will be implemented in accordance with the protocol, the 
ICH Harmonized Tripartite Guid elines for Good Clinical Practices, with applicable local 
regulations (including US Code of Federal Regulations [CFR] Title 21 and European Directive 2001/20/EC), and with the ethical principles la id down in the Declar ation of Helsinki.  
12.2. Institutional Review Board (IRB), Research Ethics Board (REB) and Independent 
Ethics Committee (IEC) Approval 
The Investigator will submit this protocol, th e ICF, IB, and any other relevant supporting 
inform
ation (eg, all advertising materials or materi als given to the subject during the study) to the 
appropriate IRB/REB/IEC for revi ew and approval before study initiation. Amendments to the 
protocol and informed consent form must also  be approved by [CONTACT_1201]/REB/IEC before the 
implementation of changes in this study. 
The Investigator is responsible for providing the IRB/REB/IEC with any required information 
before or during the study, such as SAE expedited reports or study progress reports. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 66 The IRB/REB/IEC must comply with current Unit ed States (US) regulations (§21 CFR 56) as 
well as country-specific national regulations and/or local laws. 
The following documents must be provided to Ph armacyclics or its auth orized representative 
before entering subjects in this study: (1) a copy of the IRB/REB/IEC letter that grants formal 
approval; and (2) a copy of th e IRB/REB/IEC-approved ICF.  
12.3. Informed Consent 
The ICF and process must com
ply with the US re gulations (§ 21 CFR Part 50) as well as country 
specific national regulations and/or local la ws. The ICF will document the study-specific 
information the Investigator or his/her desi gnee provides to the subj ect and the subject’s 
agreement to participate.  
The Investigator or designee (designee must be listed on the Delegati on of Authority log), must  
explain in terms understandable to the subjec t the purpose and nature of the study, study 
procedures, anticipated benefits, potential risks, possible AEs, a nd any discomfort participation 
in the study may entail. This process must be documented in the subjec t’s source record. Each 
subject must provide a signed and dated ICF be fore any study-related ( nonstandard of care) 
activities are performed. The or iginal and any amended signed and dated consent forms must 
remain in each subject’s study file at the study site and be av ailable for verification by [CONTACT_33483]. A copy of each signed consen t form must be given to the subject at the 
time that it is signed by [CONTACT_423]. 
12.4. Quality Control and Quality Assurance 
Sponsor shall implement and m
aintain quality cont rol and quality assurance procedures to ensure 
that the study is conducted and data are generated, documented and reported in compliance with 
the protocol, GCP, and applicable regulatory re quirements. This study shall be conducted in 
accordance with the provisions of  the Declaration of Helsinki (October 2008) and all revisions 
thereof, and in accordance with FDA re gulations (21 CFR Parts 11, 50, 54, 56, and 312, 
Subpart D – Responsibilities of Sponsors and Inve stigators) and with th e ICH guidelines on GCP 
(ICH E6).  12.5. Protected Subject Health Information Authorization 
Information on maintain 
ing subjec t confidentiality in accordance to  individual local and national 
subject privacy regulations must be provided to each subject as part of the informed consent 
process (refer to Section 12.3), either as part of the ICF or as a separate signed document (for 
exam
ple, in the US, a site-specific HIPAA consen t may be used). The Investigator or designee 
must  explain to each subject that for the evalua tion of study results, the subject’s protected 
health information obtained during the study ma y be shared with Pharmacyclics and its 
designees, regulatory agencies, and IRBs/REBs/ IECs. As the study Sponsor, Pharmacyclics will 
not use the subject’s protected hea lth information or disclose it to a third party without applicable 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843547] authorization. It is the Investigator’s or designee’s responsibility to obtain written 
permission to use protected health information from each subject. If a subject withdraws 
permission to use protected health information, it is  the Investigator’s resp onsibility to obtain the 
withdrawal request in writing from the subject and to ensure that no further data will be 
collected from the subject. Any data collected on the subject before withdrawal will be used in the analysis of study results. 
During the review of source documents by [CONTACT_36097], the confidentiality of the 
subject will be respected with strict adhere nce to professional standards and regulations. 
12.6. Study Files and Record Retention 
The Investigator m
ust keep a reco rd of all subjects in the study. For those subjects subsequently 
excluded from enrollment, the reason(s) for exclusion is to be recorded. The Investigator/study staff must maintain adequate and accurate  records to enable the conduct 
of the study to be fully documented and the study  data to be subsequently verified. Essential 
documentation includes, but is not limited t o, the IB, signed protocols and amendments, 
IRB/REB/IEC approval letters (dated), signed Form FDA 1572 and Financial Disclosures, 
signed ICFs (including subject confidentiality information), drug dispensing and accountability 
records, shippi[INVESTIGATOR_36075]-related materials, signed 
(electronically), dated and completed CRFs, a nd documentation of CRF corrections, SAE forms 
transmitted to Pharmacyclics and notificat ion of SAEs and related reports, source 
documentation, normal laboratory values, decoding procedures for blinde d studies, curricula 
vitae for study staff, and all relevant corre spondence and other documents pertaining to the 
conduct of the study. All essential documentation will be retained by [CONTACT_12103] [ADDRESS_843548] marketing application is approved for the drug for the indicati on for which it is being 
investigated and until there are no pending or contemplated marketing applications; or, if no application is to be filed or if  the application is not approved for such indication, until [ADDRESS_843549] notify Pharmacyclics a nd obtain written approval from Pharmacyclics 
before destroying any clinical study documents or images (eg, scan, radiograph, ECG tracing) at 
any time. Should an Investigator wish to assign the study records to another party or move them 
to another location, advance writ ten notice will be given to Phar macyclics. Pharmacyclics will 
inform the Investigator of the date that st udy records may be destroyed or returned to 
Pharmacyclics. 
Pharmacyclics must be notified in advance of, and Pharmacyclics must provide express written 
approval of, any change in the maintenance of  the foregoing documents if the Investigator 
wishes to move study records to another location or assign responsibility fo r record retention to 
another party. If the Investigator  cannot guarantee the archiving re quirements set forth herein at 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843550] with all required study data  accurately recorded such th at the information matches the 
data contained in medical records (eg, physicians ’ notes, nurses’ notes, cl inic charts and other 
study-specific source documents). Authorized study site personnel (ie, listed on the Delegation of 
Authority log) will complete CRFs designed for this study according to the completion guidelines that will be provided. The Investig ator will ensure that the CRFs are accurate, 
complete, legible, and completed within a reasonable period of time. At all times, the Investigator has final responsibility for the a ccuracy and authenticity of all clinical data. 
The CRFs exist within an electronic data capture  (EDC) system with controlled access managed 
by [CONTACT_631984]. Study staff will be appropriately 
trained in the use of CRFs and application of el ectronic signatures before the start of the study 
and before being given access to the EDC system. Original data and any changes of data will be 
recorded using the EDC system, with all changes tracked by [CONTACT_135953]. The Investigator attests that  the information contained in the CRFs is true 
by [CONTACT_36100]. After database lock, the Investigator 
will receive a copy of the subject data (eg, paper, CD, or other appropriate media) for archiving 
at the study site. 
12.8. Investigational Study Drug Accountability 
Ibrutinib must be kept in a locked limited acce ss room
. The study drug must not be used outside 
the context of the protocol. U nder no circumstances should the Investigator or other site 
personnel supply PCI-[ADDRESS_843551] be noted when drug supplies are used during the 
study: 
1. Study identification number (PCYC-1129-CA) 
2. Subject identification number 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 69 3. Lot number(s) of ibrutinib or comparator dispensed for that subject 
4. Date and quantity of drug dispensed 
5. Any unused drug returned by [CONTACT_183982], the monitor will evaluate and a pprove the site’s proced ure for investigational 
product disposal/destruction to ensu re that it complies with Pharm acyclics’ requirements. If the 
site cannot meet Pharmacyclics’ requirements  for disposal/destruction, arrangements will be 
made between the site and Pharmacyclics or  its representative, for return of unused 
investigational product. Before disposal/destr uction, final drug accountability and reconciliation 
must be performed by [CONTACT_269624]/or two authorized study site personnel. 
All study supplies and associated documentation w ill be regularly reviewed and verified by [CONTACT_36102]. 
12.9. Study Monitoring/Audit Requirements 
Representatives of Pharmacyclics or its de s
ignee will monitor this study until completion. 
Monitoring will be conducted through personal visits with the Investigator and site staff, remote 
monitoring, as well as any appropriate communica tions by [CONTACT_2319], fax, email, or telephone. The 
purpose of monitoring is to ensure that the study  is conducted in compliance with the protocol, 
standard operating procedures (SOPs), and other written instructions and regulatory guidelines, 
and to ensure the quality and integrity of the data. This study is also subject to reviews or audits. 
To assure the accuracy of data collected in th e CRFs, it is mandatory th at the monitor/auditor 
have access to all original source documents, in cluding all electronic medical records (EMR) at 
reasonable times and upon reasona ble notice. During the review of source documents, every 
effort will be made to maintain  the anonymity and confidential ity of all subjects during this 
clinical study. However, because of the experiment al nature of this treatment, the Investigator 
agrees to allow the IRB/REB/IEC, representative s of Pharmacyclics, its designated agents and 
authorized employees of the appropriate Regulator y Authority to inspect the facilities used in 
this study and, for purposes of veri fication, allow direct access to th e hospi[INVESTIGATOR_393027]. A statement to this effect will be included in the informed 
consent and permission form authorizing th e use of protected health information. 
Pharmacyclics or its authorized representative ma y perform an audit at any time during or after 
completion of this study. All study-related doc umentation must be made available to the 
designated auditor. In addition, a representative of the FDA or other Regulatory Agencies may 
choose to inspect a study site at  any time before, during, or after completion of the clinical study. 
In the event of such an inspect ion, Pharmacyclics will be availabl e to assist in the preparation. 
All pertinent study data should be made available as requested to the Regulatory Authority for 
verification, audit, or inspection purposes. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843552] the 
study according to the current protocol; will read and understand the IB; will obtain 
IRB/REB/IEC approval to conduct the study; wi ll obtain informed consent from each study 
participant; will maintain and supply to the S ponsor or designee, auditors and regulatory 
agencies adequate and accurate records of study activity and drug accountability for study-related monitoring, audits, IRB/REB/IEC reviews and regulatory inspecti ons; will report SAEs 
to the Sponsor or designee and IRB/ REB/IEC according to the specifics outlined in this protocol; will personally conduct or supervise the study; and will ensure that colleagues 
participating in the study are informed a bout their obligations in meeting the above 
commitments. 
12.11. Sponsor Responsibilities 
A comp 
lete list of the Sponsor responsibilities is outlined in the clinical trial research agreement 
and in the laws and regulation of  the country in which the resear ch is conducted. In summary, the 
Sponsor will select qualified Investigators, provide them with the information they need to 
properly conduct the study, ensu re adequate monitoring of th e study, conduct the study in 
accordance with the general investigational plan and protocols and promptly inform 
Investigators, health and regulatory agencies/a uthorities as appropria te of significant new 
adverse effects or risks w ith respect to the drug. 
12.12. Financial Disclosure 
A separate financial agre
ement will be made between each Principal Investigator [INVESTIGATOR_183920]. 
For this study, each Investigator and Subinvest igator (as designated on the Form FDA1572) will 
provide a personally signed Financial Disclosure Form in accordance with § [ADDRESS_843553] or inju
ry, appropriate medical care as determined by [CONTACT_3786]/designee will be provided. 
If a bodily injury is sustained, resulting directly  from the use of the study drug, Pharmacyclics 
will reimburse for reasonable physician fees and medical expenses necessary for treatment of 
only the bodily injury which is not covered by [CONTACT_941] s ubject’s medical or hospi[INVESTIGATOR_36076], 
provided that the injury is not due to a negligent or wrongful act or omission by [CONTACT_737]/ 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 71 study staff. The ICF will include a description of this reimbursement policy, incorporating 
country-specific national regulations and/or local laws. Financia l compensation for lost wages, 
disability or discomfort due to  the study is not available. 
Clinical trial insurance has been undertaken acco rding to the laws of the countries where the 
study will be conducted. An insurance certificate will be made available to th e participating sites 
at the time of study initiation. 
12.14. Protocol Amendments 
Pharmacyclics will initia
te any change to the pr otocol in a protocol amendment document. The 
amendment will be submitted to the IRB/REB/IEC t ogether with, if applicable, a revised model 
ICF. Written documentation of IRB/REB/IEC and re quired site approval must be received by 
[CONTACT_183984]. Additionally under this 
circumstance, information on any change in risk and/or change in scope must be provided to 
subjects already actively participating in the st udy, and they must read, understand and sign each 
revised ICF confirming willingness to remain in the trial. 
No other significant or consistent change in  the study procedures, except to eliminate an 
immediate hazard, shall be effected without th e mutual agreement of the Investigator and 
Pharmacyclics. 
12.15. Publication of Study Results 
Pharmacyclics m
ay use the results of this clini cal study in registration documents for Regulatory 
Authorities in the US or abroad. The results may al so be used for papers, abstracts, posters, or 
other material presented at scient ific meetings or published in prof essional journals or as part of 
an academic thesis by [CONTACT_39595]. In all cas es, to avoid disclosures that could jeopardize 
proprietary rights and to ensure a ccuracy of the data, Pharmacyclics reserves the right to preview 
all manuscripts and abstracts related to this  study, allowing Pharmacyclics sufficient time to 
make appropriate comments before submission for publication. 
In most cases, the Investigators at the sites with th e highest accruals of eligible subjects shall be 
listed as lead authors on manuscripts and repor ts of study results. The Medical Monitor, study 
director and/or lead statistician may also be included in the list of authors. This custom can be 
adjusted upon mutual agreement of the authors and Pharmacyclics and in accordance with 
current standards for authorship as recorded in professional conferen ce and journal submission 
instructions. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 72 12.16. Study Discontinuation 
The Sponsor reserves the right to  terminate the study at any tim
e. Should this be necessary, both 
the Sponsor and the Investigator  will arrange discon tinuation procedures. In terminating the 
study, the Sponsor and the Investigator will assure  that adequate consideration is given to the 
protection of the subjects’ interests. 
  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 73 13. REFERENCES  
Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor (PCI-[ZIP_CODE]) has significant 
activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2012;31:88-94. 
Measurement of Therapeutic Response in Chronic Graft-versus-Host Disease. American Society for 
Blood and Marrow Transplantation (ASBMT) Web site. http://www.asbmt.org/?29. Accessed April 9, 
2014. 
Anasetti C, Logan BR, Lee SJ, et al. Increased inci dence of chronic graft-versus-host disease (GVHD) 
and no survival advantage with filgrastim-mobilized peripheral blood stem cells (PBSC) compared to 
bone marrow (BM) transplants from unrelated donors: results of Blood and Marrow Transplant Clinical 
Trials Network (BMT CTN) Protocol 0201, a Phase III, prospective, randomized trial. ASH Annual 
Meeting Abstracts 2011;118: Abstract 1. 
Appelbaum FR, Haematopoietic cell transplanta tion as immunotherapy. Nature 2001; 411:385-9. 
Arai S, Jagasia M, Storer B, et al. Global and organ-specific chronic graft-versus-host disease severity 
according to the 2005 NIH Consensus Criteria. Blood. 2011;118:4242-49.  
Arai S, Sahaf B, Narasimhan B, et al. Prophylactic rituximab after allogeneic transplantation decreases B-
cell alloimmunity with low chronic GVHD incidence. Blood 2012;119:6145-6154. 
Baird K, Pavletic SZ. Chronic graft versus hos t disease. Curr Opin Hematol. 2006;13:426-435.  
Bishop GA, Haxhinasto SA, Stunz LL, et al. Antigen-specific B-lymphocyte activation. Crit Rev 
Immunol 2003;23:165–197.  
By[CONTACT_9063], Furman RR, Coutre SE, et al. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic 
Leukemia. N Engl J Med 2013;369:32-42. 
Canninga-van Dijk MR, van er Straaten HM. Fijnheer R, et al. Anti-CD20 monoclonal antibody treatment 
in [ADDRESS_843554] diseae. Bl ood. 2004; 104:2603-2606. 
Child CG, Turcotte JG. “Surgery and portal hy pertension”. In Child CG. The liver and portal 
hypertension. Philadelphia:Saunders. 1964. pp. 50-64. Chronic GVHD Activity Assessment-Clinician. Source: http://asbmt.affiniscape.com/associations /[ZIP_CODE]/files/ResponseCriteriaAPPENDIXAFormA.pdf 
Chronic GVHD Activity Assessment - Patient Self Report. Source: http://asbmt.affiniscape.com/associations/[ZIP_CODE]/ files/ResponseCriteriaAPPENDIXBFormB.pdf 
Common Terminology Criteria for Adverse Events (C TCAE), Version 4.03, Published June 14, 2010. 
Couriel DR, Saliba R, Escalón MP, et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 2005;130:409-17. 
Cutler C, Miklos D, Kim HT et al. Rituximab for steroid-refractory chronic graft-vs.-host disease. Blood 
2006;108:756-762. 
Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutin ib is an irreversible molecular inhibitor of ITK 
driving a Th1 selective pressure in T-lymphocytes. Blood. 2013;122:2539-49.  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843555] disease: I. Diagnosis and staging working group 
report. Biol Blood Marrow Transplant 2005;11:945-956. 
Flowers ME, Apperley JF, van Besien K, et al. A multicenter prospective phase [ADDRESS_843556] disease. Blood 2008a; 112: 2667-74. 
Flowers ME, Storer B, Carpenter P, et al. Treatme nt change as a predictor of outcome among patients 
with classic chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008b;14:1380-1384.  
Fraser CJ, Bhatia S, Ness K, et al. Impact of chronic graft-versus-host disease on the health status of 
hematopoietic cell transplantation survivors: a repor t from the Bone Marrow Transplant Survivor Study. 
Blood 2006; 108: 2867-73. 
Gilman AL, Chan KW, Mogul A, et al. Hydroxychloroquine for the treatment of chronic graft-versus-host 
disease. Biol Blood Marrow Transplant 2000;6:327-34. 
Hale GA, Shrestha S, Le-Rademacher J, et al. A lternate donor hematopoietic cell transplantation (HCT) 
in non-Hodgkin lymphoma using lower intensity conditioning: A Report from the CIBMTR. Biol Blood 
Marrow Transplant 2012;18:1036-1043. 
Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic 
target for treatment of chronic lymphocytic leukemia and is effectively targeted by [CONTACT_9090]-[ZIP_CODE]. Blood. 2011;117:6287-96. 
Holler E. Risk assessment in haematopoietic stem cel l transplantation: GvHD prevention and treatment. 
Best Pract Res Clin Haematol. 2007;20:281-294.  
ICH-E2A, Federal Register, Vol 60, No.40, March, 1995. Inamoto, Y, Storer, BE, Lee, SJ et al. Failure-free su rvival after second-line systemic treatment of chronic 
graft-versus-host disease. Blood 2013;121:2340-6.  Investigator's Brochure. Ibrutinib. Version 9: 30June 2015. Pharmacyclics LLC; Janssen Research & 
Development, LLC. Jaglowski SM, Vasu S, Geyer S, et al. Immune Re constitution at Days [ADDRESS_843557] disease. 
ASH Annual Meeting Abstracts;2012;120:1949. Johnston LJ, Brown J, Shizuru JA, et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host 
disease. Biol Blood Marrow Transplant 2005;11:47-55. 
Koc S, Leisenring W, Flowers ME, et al. Therapy for chronic graft-versus-host disease: a randomized 
trial comparing cyclosporine plus prednisone ve rsus prednisone alone. Blood 2002;100:48-51. 
Kulkarni S, Powles R, Sirohi B, et al. Thali domide after allogeneic haematopoietic stem cell 
transplantation: activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplant 
2003;32:165-70. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 75 Lee cGVHD Symptom Scale. http ://www.uniklinikum-regensburg.de /imperia/md/content/kliniken-
institute/haematologie-onkologie/gvhd/deutsch/lee-symptom_scale.pdf 
Lee JW, Deeg HJ. Prevention of chronic GVHD. Best Pract Res Clin Haematol. 2008;21:259-270.  
Lee SJ, Kim HT, Ho VT, et al. Quality of life associat ed with acute and chronic graft-versus-host disease. 
Bone Marrow Transplant 2006;38:305-10. 
Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with 
treatment-related mortality and re lapse. Blood 2002;100: 406-14. 
Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215-233.  
Lee SJ. Have we made progress in the management of chronic graft-vs-host disease? Best Pract Res Clin 
Haematol. 2010;23:529-535.  
Logan A, Sahaf B, Zhang B, et al. Impaired B Cell clonotype diversification after allogeneic 
hematopoietic cell transplantation predicts graft- versus-host disease. Biol Blood Marrow Transplant 
2013;19:S148-S149. 
Martin PJ, Storer BE, Rowley SD, et al. Evalua tion of mycophenolate mofetil for initial treatment of 
chronic graft-versus-host disease. Blood 2009;113:5074-82. 
Miklos DB, Kim H, Zorn E, et al. Antibody R esponse to DBY [CONTACT_631985]. Blood 2004;103:353-359. 
Miklos DB, Kim HT, Miller KH et al. Antibody responses to H-Y minor histocompatibility antigens 
correlate with chronic graft-versus-host di sease and disease remission. Blood 2005;105:2973-2978. 
Mohamed AJ, Yu L, Backesjo CM, et al. Bruton's tyrosine kinase (Btk): function, regulation, and 
transformation with special emphasis on the PH domain. Immunol Rev. 2009;228:58-73. 
Mohty M, Marchetti N, El-Cheikh J, et al. Rituxi mab as salvage therapy for refractory chronic GVHD. 
Bone Marrow Transplant 2008;41:909-911. Morris SC, Cheek RL, Cohen PL, Eisenberg RA. Allotype-specific immunoregulation of autoantibody 
production by [CONTACT_207104] B cells in chronic graft-ve rsus host disease. J Im munol. 1990;144:916-922. 
Ofran Y, Kim HT, Brusic V, et al. Diverse pattern s of T cell response against multiple newly identified 
human Y chromosome encoded minor histocompatibilit y epi[INVESTIGATOR_322]. Clin Cancer Res 2010; 16: 1642-51. 
Pan Z, Scheerens H, Li SJ, et al. Discovery of selectiv e irreversible inhibitors for Bruton's tyrosine kinase. 
ChemMedChem 2007;2:58-61. 
Parker PM, Chao N, Nademanee A, et al. Thalidom ide as salvage therapy for chronic graft-versus-host 
disease. Blood 1995; 86:3604-9. 
Pavletic SZ, Martin P, Lee SJ, et al. Measuring ther apeutic response in chronic graft-versus-host-disease: 
national institutes of health consensus development proj ect on criteria for clinical trials in chronic graft-
versus-host-disease: IV. Response criteria worki ng group report. Biol. Blood Marrow Transplant. 
2006;12:252-66. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 76 Perez-Simon JA, Kottaridis PD, Martino R, et al. Nonmyeloablative transplantation with or without 
alemtuzumab: comparison between 2 prospective studi es in patients with lymphoproliferative disorders. 
Blood. 2002;100:3121-3127. 
Pi[INVESTIGATOR_43221] J, Kurland B, Chai X, et al. Patient-reported quality of life is associated with severity of chronic 
graft-versus-host disease as measured by [CONTACT_175716]: report on baseline data from the Chronic GVHD 
Consortium. Blood. 2011;117:4651-4657.  
Pugh RN, Murray-Lyon IM, Dawson L, Pi[INVESTIGATOR_9051], Williams R . “Transection of the oesophagus for 
bleeding oesophageal varices”. The British journal of surgery , 1973;60: 646-9. 
Ratanatharathorn V, Ayash L, Reynolds C, et al. Treatment of chronic graft-versus-host disease with anit-
CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003;9:505-511. 
Response Criteria for Partial Response and Progression in cGVHD. 
http://asbmt.affiniscape.com/associations/[ZIP_CODE]/fil es/ResponseCrit e riaAPPENDIXC_DCalculations.pdf 
Sahaf B, Arai S, Otani J, et al. Rituximab Provides Steroid-Sparing Therapy in New-Onset Chronic Graft-Versus-Host Disease. ASBMT 2013 (manuscript in preparation). 
Sarantopoulos S, Stevenson KE, Kim HT, et al. A ltered B-cell homeostasis and excess BAFF in human 
chronic graft-versus-host diseas e. Blood. 2009;113:3865-3874.  
Satterthwaite AB, Witte ON. The role of Bruton's ty rosine kinase in B cell development and function: a 
genetic perspective. Immu nol Rev 2000;175:120-7. 
Schroeder MA, DiPersio JF. Mouse models of graf t-versus-host disease: advances and limitations. Dis 
Model Mech;2011;4:318-333. 
Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS. The role of B cells in the 
pathogenesis of graft-versus-hos t disease. Blood. 2009;114:4919-4927. 
Shinners NP, Carlesso G, Castro I, et al. Bruton' s Tyrosine Kinase Mediates NF-kappa B Activation and 
B Cell Survival by B Cell-Activating Factor Receptor of the TNF-R Family. The Journal of Immunology. 
2007;179:3872-3880. 
Shulman HM, Kleiner D, Lee SJ, et al. Histopathologic diagnosis of chronic graft-versus-host disease: 
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic 
Graft-versus-Host Disease: II. Pathology Work ing Group Report. Biol Blood Marrow Transplant 
2006;12:31-47. 
Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 up date of recommendations for the use of white blood 
cell growth factors: An evidence-based clinical  practice guideline. J Clin Oncol 2006;24:3187-205.  
Socie G, Stone JV, Wingard JR, et al. Long-term surv ival and late deaths after allogeneic bone marrow 
transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. 
N Engl J Med. 1999;341:14-21. 
Sullivan KM, Witherspoon RP, Storb R, et al. Prednisone and azathioprine compared with prednisone and 
placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged 
thrombocytopenia after allogeneic marr ow transplantation. Blood 1988;72:546-54. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 77 Sutherland HJ, Fyles GM, Adams G et al. Quality of life following bone marrow transplantation: a 
comparison of patient reports with population nor ms. Bone Marrow Transplant. 1997;19:1129-1136. 
Syrjala KL, Martin PJ, Lee SJ. Delivering care to long-term adult survivors of hematopoietic cell 
transplantation. J Clin Oncol. 2012;30:3746-51. 
Thomas ED, Lochte HL Jr, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients 
receiving radiation and chemotherapy. N Engl J Med 1957; 257:491-6. 
  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 78 14. APPENDICES  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843558]-Treatment/ 
Follow-up Phase 
Study Weeks  1 1 2 5 9, 13, 17,  
21, 25 
q4 weeks 37 and every 
12 weeks 
thereafter Progressive 
Disease Visit End-of- 
Treatment 
Visit 
([ADDRESS_843559] dose of 
study drug) Response Follow-
up Visits 
(Until progressive 
disease) 
q12 weeks Survival 
Follow-up
q12 weeks 
Study Day of study week  1 2 1 1 1 1     
Study Windows -42 days On time  ±3 days  anytime ± 7 days  ± 7 days ± 7 days  
Study Drug Administration 
ibrutinib 420mg/280mg/140mg 
dispensing  x   x x x     
ibrutinib administration  Continuous daily dosing      
Administrative Procedures 
Informed consent x           
Confirm eligibility/enrollment 
checklist x x          
Medical history and Demographics x           
GVHD/Transplant History x          
Safety Assessments 
DLT Assessment (Phase 1b)     x       
Physical exam (height at Screening 
only) xa xa  xb xa xb xa xa xa xb  
KPS status x x   x x x x x x  
Vital signs x x  x x x x x x x  
Oxygen saturation/PFTc x           
Survival           x 
ECG d x  If clinically indicated (eg, subjec ts with palpi[INVESTIGATOR_814], lightheadedness) 
Clinical Laboratory Assessments 
Hematology x x  x x x x x x x  
Serum Chemistry x x  x x x x x x x  
Coagulation (PT, INR, and aPTT) x           
Pregnancy test e x x          
Hepatitis serologies x           
Donor/host chimerism x     Weeks 13, 25 x x x x  
Quantitative serum immunoglobulins 
(IgA, IgG and IgM) x     Weeks 13, 25 x x x   
Immunosupressant Levels x As needed during treatment   
PK  xg xg xg        
PD  xh xh xh  Week 9, 13      
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843560]-Treatment/ 
Follow-up Phase 
Study Weeks  1 1 2 5 9, 13, 17,  
21, 25 
q4 weeks 37 and every 
12 weeks 
thereafter Progressive 
Disease Visit End-of- 
Treatment 
Visit 
([ADDRESS_843561] dose of 
study drug) Response Follow-
up Visits 
(Until progressive 
disease) 
q12 weeks Survival 
Follow-up
q12 weeks 
Study Day of study week  1 2 1 1 1 1     
Study Windows -42 days On time  ±3 days  anytime ± 7 days  ± 7 days ± 7 days  
Efficacy Assessments 
cGVHD Assessment (NIH Form) x x   x Weeks 13, [ADDRESS_843562] dose of study drug   
Biomarkers 
T/B/NK cell counts xi xi xi xi  Week 9, 13      
Biomarkers  x   x Weeks 13, 25 Weeks 37, 49  x   
Abbreviations: AEs=adverse events ; aPTT=activated part ial thromboplastin time; ECG=electrocardiogram; K PS=Karnofsky Performance  Status; EOT=end-of-treatment; 
INR=international normalized ration; PD=pharmacodynamic; PK=pha rmacokinetics; PO=orally; PT=prothrombin time; q4 weeks=every 4 weeks; q12 weeks=every 12 weeks 
 
Footnote:  
a. Physical Examination includes: general appear ance of subject, examination of skin, ey es and fundi, ears, no se, throat, lungs, h eart, abdomen, extremities, 
musculoskeletal system, lymphatic  system, and nervous system. 
b. Only a limited symptom-directed physical examination is required. Review of symptoms should include inquiry of ocular symptoms;  subjects should be 
referred to an ophthalmologist for a formal examination if any Grade ≥2 symptoms are reported. 
c. Oxygen saturation by [CONTACT_631986]. If not done, then PFT with FEV1 required within 6 months of Screening. 
d. ECG’s may be performed at the Investigator’s discretion, particul arly in subjects with arrhythmic symptoms (eg, palpi[INVESTIGATOR_814], l ightheadedness) or new onset 
of dyspnea. 
e. Women of childbearing potential only. Serum pregnancy test required at Screening and urine pregnancy test required at Day [ADDRESS_843563] be ruled out by [CONTACT_375842]. 
f. Lee cGVHD Symptom Scale should be  completed prior to any assessments, and before being clinically evaluated by [CONTACT_620626].  
g. Pharmacokinetic (PK) samples will be drawn for all subjects according to the schedule in Section [IP_ADDRESS]. Additional PK samples will be collected for 
subjects treated wi
th concomitant a moderate or strong CYP3A inhibitors while on ibrutinib treatment according to the schedule in Section [IP_ADDRESS] . 
h. Pharmacodynamic (PD) sampling for PCYC will be performed on selected days at predose and post-dose. Refer to Table 3  for more details. 
i. T/B/NK sampling for PCYC will be performed on selected days at predose and post-dose. Refer to Table 4  for more details. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
 Final 
Pharmacyclics LLC Proprietary and Confidential Page 81 Appendix B. NIH Defined Diagnostic or Di stinctive Features of Chronic GVHD 
Organ or Site Diagnostic  
(Sufficient to Establish 
the Diagnosis of 
Chronic GVHD) Distinctive  
(Seen in Chronic GVHD, 
but Insufficient Alone to 
Establish a Diagnosis of 
Chronic GVHD) Other Features* Common  
(Seen with Both Acute 
and Chronic GVHD) 
Skin Poikiloderma  
Lichen planus-like 
features 
Sclerotic features 
Morphea-like features  
Lichen sclerosus-like 
features Depi[INVESTIGATOR_631947], 
splitting, or brittle features 
Onycholysis Pterygium unguis 
Nail loss (usually symmetric; 
affects most nails)
†   
Scalp and body hair  New onset of scarring or 
nonscarring scalp alopecia 
(after recovery from 
chemoradiotherapy) 
Scaling, papulosquamous 
lesions Thinning scalp hair, 
typi[INVESTIGATOR_91608], coarse, 
or dull (not explained by 
[CONTACT_91646]) 
Premature gray hair  
Mouth Lichen-type features Hyperkeratotic plaques 
Restriction of mouth Xerostomia 
Mucocele 
Mucosal atrophy 
Pseudomembranes
† 
Ulcers†  Gingivitis 
Mucositis 
Erythema 
Pain 
Eyes  New onset dry, gritty, or 
painful eyes‡ 
Cicatricial conjunctivitis Keratoconjunctivitis sicca
‡ 
Confluent areas of punctate 
keratopathy Photophobia Periorbital 
hyperpi[INVESTIGATOR_91609] (erythema of 
the eyelids with edema)  
Genitalia Lichen planus-like 
features  
Vaginal scarring or 
stenosis Erosions† 
Fissures† 
Ulcers†   
GI tract Esophageal web 
Strictures or stenosis in 
the upper to mid third of the esophagus
†  Exocrine pancreatic 
insufficiency Anorexia Nausea 
Vomiting 
Diarrhea Weight loss 
Failure to thrive (infants 
and children) 
Liver    Total bilirubin, alkaline 
phosphatase >[ADDRESS_843564]† 
ALT or AST >[ADDRESS_843565]† 
Lung Bronchiolitis obliterans 
diagnosed with lung biopsy Bronchiolitis obliterans 
diagnosed with PFTs and radiology
‡  BOOP 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
 Final 
Pharmacyclics LLC Proprietary and Confidential Page 82 Organ or Site Diagnostic  
(Sufficient to Establish 
the Diagnosis of 
Chronic GVHD) Distinctive  
(Seen in Chronic GVHD, 
but Insufficient Alone to 
Establish a Diagnosis of 
Chronic GVHD) Other Features* Common  
(Seen with Both Acute 
and Chronic GVHD) 
Muscles, 
fascia, joints Fasciitis Joint stiffness or 
contractures secondary to sclerosis Myositis or polymyositis
‡ Edema 
Muscle cramps 
Arthralgia or arthritis  
Hematopoietic and immune   Thrombocytopenia 
Eosinophilia 
Lymphopenia 
Hypo- or 
hypergammaglobulinemi
a
Autoantibodies 
(AIHA and ITP)  
Other   Pericardial or pleural 
effusions 
Ascites 
Peripheral neuropathy 
Nephrotic syndrome 
Myasthenia gravis 
Cardiac conduction 
abnormality or cardiomyopathy  
GVHD indicates graft-versus-host disease;  ALT, alanine ami notransferase; AST, aspartat e aminotransferase; BOOP, 
bronchiolitis obliterans organi zing pneumonia; PFTs, pulmonary  function tests; AIHA, autoimmune hemolytic anemia; ITP, 
idiopathic thrombocytopenic purpura. 
* Can be acknowledged as part of the chronic GVHD symptomatology if the diagnosis is confirmed. 
† In all cases, infection, drug effects, maligna ncy, or other causes must be excluded. 
‡ Diagnosis of chronic GVHD requires biopsy or radiology confirmation (or Schirmer test for eyes). 
Source: Filipovich 2005  
 
  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
 Final 
Pharmacyclics LLC Proprietary and Confidential Page 83 Appendix C. Karnofsky Perf ormance Status Scores 
% Karnofsky Performance Status 
100 Normal; no complaints; no evidence of disease. 
90 Able to carry on normal activity; minor  signs or symptoms of disease. 
80 Normal activity with effort; some signs or symptoms of disease. 
[ADDRESS_843566] of his or her needs. 
50 Requires considerable assistance and frequent medical care. 
40 Disabled, requires special care and assistance. 
30 Severely disabled; hospi[INVESTIGATOR_631948]. 
20 Hospi[INVESTIGATOR_20545]; very sick; active supportive tr eatment necessary. 
10 Moribund; fatal processes progressing rapi[INVESTIGATOR_375]. 
0 Dead. 
 
  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment [ADDRESS_843567] disease. 
 Cellcept Cyclosporine Etanercept or other FDA-approved TNF α inhibitors 
Extracorpeal photophoresis (ECP) Imatinib Methotrexate Pentostatin Rituximab Sirolimus Tacrolimus
 
 
  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
 Final 
Pharmacyclics LLC Proprietary and Confidential Page 85 Appendix E. Lee cGVHD Symptom Scale 
Identification (Name):__________________________  Date:_____________  
chronic GVHD Symptom Scale  
By [CONTACT_51085] (1) number per line, please indicate how much you have been bothered by [CONTACT_631987]:  
SKIN:  Not at 
all  Slightly  Moderately  Quite a 
bit  Extremely  
1.  Abnormal skin color………………..  0  1  2  3  4  
2.  Rashes………………………………  0  1  2  3  4  
3.  Thickened skin………… ………...  0  1  2  3  4  
4.  Sores on skin……………………….  0  1  2  3  4  
5.   Itchy skin………….  0  1  2  3  4  
EYES AND MOUTH:  Not at 
all  Slightly  Moderately  Quite a 
bit  Extremely  
6.  Dry eyes…………………………….  0  1  2  3  4  
7.  Need to use eye drops frequently..  0  1  2  3  4  
8.  Difficulty seeing clearly……………  0  1  2  3  4  
9.  Need to avoid certain foods due to 
mouth pain………………………….  0 1 2 3 4 
10.  Ulcers in mouth…………………….  0 1 2 3 4 
11.  Receiving nutrition from an intravenous line or feeding tube....  0 1 2 3 4 
BREATHING:  Not at 
all Slightly  Moderately  Quite a 
bit Extremely  
12.  Frequent cough…………………….  0 1 2 3 4 
13. .  Colored sputum…………………… [ADDRESS_843568]……...  0 1 2 3 4 
16. Need to use oxygen…………….. 0 1 2 3 4 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
 Final 
Pharmacyclics LLC Proprietary and Confidential Page 86 EATING AND DIGESTION: Not at 
all Slightly Moderately Quite a 
bit Extremely 
17. Difficulty swallowing solid foods…. 0 1 2 3 4 
18. Difficulty swallowing liquids………. 0 1 2 3 4 
19. Vomiting……………………………. 0 1 2 3 4 
20. Weight loss………………………… 0 1 2 3 4 
MUSCLES AND JOINTS:  Not at 
all Slightly Moderately Quite a 
bit Extremely 
21. Joint and muscle aches.............…. 0 1 2 3 4 
22. Limited joint movement…......……. 0 1 2 3 4 
23. Muscle cramps…………………….. 0 1 2 3 4 
24. Weak muscles……………………... 0 1 2 3 4 
Energy:  Not at 
all Slightly Moderately Quite a 
bit Extremely 
25. Loss of energy…………………….  0 1 2 3 4 
26. Need to sleep more/take naps…..  0 1 2 3 4 
27. Fevers………………………………  0 1 2 3 4 
MENTAL AND EMOTIONAL:  Not at 
all Slightly Moderately Quite a 
bit Extremely 
28. Depression…………………………  0 1 2 3 4 
29. Anxiety……………………………...  0 1 2 3 4 
30. Difficulty sleepi[INVESTIGATOR_007]………………….  0 1 2 3 4 
 
 
Source:  
http://www.uniklinikum-regensburg.de/imperia/md/content/kliniken-institute/haematologie-
onkologie/gvhd/deutsch /lee-symptom_scale.pdf 
 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
 
Pharmacyclics LLC Proprietary and Confidential Page 87 Appendix F. Chronic GVHD Activity Assessment – Clinician 
Guidelines for completing the Chronic GV HD Activity Assessment – Clinician Form: 
 
 EYES- If Schirmer’s Tear test is not pe rformed please complete the NIH eye score. 
 LUNGS-Complete full PFTs if po ssible but FEV1 is required. 
 
--If FEV1 is normal at baseline, repeat assessment not required unless progression is suspected. Complete NIH lung 
score in place of FEV1 at each visit.  --If FEV1 is abnormal at baseline then reassessment Q12 weeks is required. 
 GRIP STRENGTH-Not necessary to complete  [ADDRESS_843569]-Complete only at baseline  RANGE OF MOTION—Complete photographic ROM score and NIH joint/fascia score 
 ** If a change in score is considered to be due to a cause ot her than cGVHD please note and mark  NE (not evaluable) for cGVHD 
score.  
 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
 
Pharmacyclics LLC Proprietary and Confidential Page 88 FORM A  
Current Patient Weight: ___________________ Today’s Date: ________________________ MR#/Name: ____________________  
 
CHRONIC GVHD ACTIVITY ASSESSMENT- CLINICIAN 
 
Component  Findings Scoring (see skin score worksheet) 
Skin 
 Erythematous rash of any sort % BSA (max 100%) 
Moveable sclerosis % BSA (max 100%) 
Non-moveable sclerosis (hidebound/non-pi[INVESTIGATOR_571134]) or subcutaneous 
sclerosis/fasciitis % BSA (max 100%) 
Ulcer(s): select the largest ulcerative lesion, and measure its largest dimension in cm 
and mark location of ulcer Location: ___________________ Largest dimension: __________cm 
Eyes 
Bilateral Schirmer’s Tear Test 
(without anesthesia) in persons 9 years or older
 Right Eye:                                             mm of wetting Left Eye:                                                         mm of wetting 
Mouth 
 Mucosal change  No evidence of 
cGVHD   Mild   Moderate  Severe 
 Erythema   None  0   Mild erythema or moderate 
erythema (<25%)  1   Moderate (≥ 25%) or Severe 
erythema (<25%)  2   Severe erythema ( ≥25%) 3   
 Lichenoid   None  0   Hyperkeratotic changes(<25%) 1   Hyperkeratotic changes(25-
50%)  2   Hyperkeratotic changes 
(>50%)  3   
 Ulcers   None  0   None  0   Ulcers involving ( ≤20%)  3   Severe ulcerations 
(>20%)  6   
 Mucoceles*  None  0   1-5 mucoceles  1   6-10 scattered mucoceles  2   Over 10 mucoceles  3   
         
 *Mucoceles scored for lower labial and 
soft palate only   Total score for all 
mucosal changes   
Blood Counts  Platelet Count 
K/uL ULN 
K/uL Total WBC 
K/uL ULN 
K/uL % Eosinophils 
% 
Liver Function Tests Total serum bilirubin 
mg/dL ULN 
mg/dL ALT 
U/L ULN 
U/L Alkaline Phosphatase 
U/L ULN  
U/L 

Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
 
Pharmacyclics LLC Proprietary and Confidential Page 89 Gastrointestinal-Upper    
• Early satiety OR  
• Anorexia OR  
• Nausea & Vomiting  0= no symptoms  1=mild, occasional symptoms, with little reduction in oral intake during the past week
  
2=moderate, inte rmittent symptoms, with some reduction in oral intake during the past week  
3=more severe or persistent symptoms throughout the day, with marked reduction in oral intake, on almost every day of the past week  
Gastrointestinal-Esophageal  
• Dysphagia OR  • Odynophagia  0= no esophageal symptoms  
1=Occasional dysphagia or odynophagia with solid food or pi[INVESTIGATOR_571135] 
 
2=Intermittent dysphagia or odynophagia with solid foods or pi[INVESTIGATOR_3353], but not for liquids or soft foods, during the past week  
3=Dysphagia or odynophagia for almost all oral intake, on almost every day of the past week  
Gastrointestinal-Lower =  
• Diarrhea  0= no loose or liquid stools during the past week   
1= occasional loose or liquid stools, on some days during the past week  
2=intermittent loose or liquid stools throughout the day, on almost every day of the past week,  without requiring intervention to prevent or correct volume depletion  
3=voluminous diarrhea on almost every day of the past week,  requiring intervention to prevent or correct volume depletion  
Lungs  
• Bronchiolitis Obliterans   Pulmonary Function Tests with Diffusing Capacity (attach 
report for person> 5 yrs old)  FEV-1  
 
% Predicted Single Breath DLCO (adjusted for hemoglobin)  
 
% Predicted 
Health Care Provider Global Ratings:  
In your opi[INVESTIGATOR_1649], do you think that this 
patient’s chronic GVHD is mild, 
moderate or severe?  
0=none  
1= mild  2=moderate  
3=severe   
Where would you rate the severity of this patient’s chronic GVHD symptoms on the following scale, where [ADDRESS_843570] severe cGVHD symptoms 
possible:  
 
 [ADDRESS_843571] month would you say that this 
patient’s cGVHD is  
+3= Very much better  
+2= Moderately better  
+1= A little better  0= About the same  -1=A little worse  
-2=Moderately worse  
-3=Very much worse  
Functional Performance (in 
persons >4 years old) 
• Walk Time 
• Grip Strength Total Distance Walked in 2 Minutes: 
 Number of laps: _______ (x 50 feet) + final partial lap: _____ feet 
= ______ feet walked in 2 minutes Grip Strength (Dominant Hand) Range of Motion: 
o Not performed 
o Physical Therapy Report Attached Trial #1 
 
psi Trial #2 
 
psi Trial #3 
 
psi 
Score Lansky Performance Status Scale Definitions (circle from 0-100)  
(persons < 16 years old) Karnofsky Performance Status Scale Definitions (circle from 0-100) 
(persons 16 years or older) 
100  Fully active, normal  Normal no complaints; no evidence of disease  
90  Minor restrictions in physically strenuous activity  Able to carry on normal activity; minor signs or symptoms of disease  
80  Active, but tires more quickly  Normal activity with effort; some signs or symptoms of disease  
70  Both greater restriction of and less time spent in play activity  Cares for self; unable to carry on normal activity or to do a ctive work  
60  Up and around, but minimal active play; keeps busy with quieter activities  Requires occasional assistance but is able to care for most personal needs 
50  Gets dressed but lies around much of the day, no active play but able to participate in all quiet play and activities  Requires considerable assistance and frequent medical care  
40  Mostly in bed; participates in quiet activities  Disabled; requires special care and assistance  
30  In bed; needs assistance even for quiet play  Severely disabled; hospi[INVESTIGATOR_571136]  
20  Often sleepi[INVESTIGATOR_007]; play entirely limited to very passive activities  Very sick; hospi[INVESTIGATOR_3115]; active supportive treatment 
necessary  
10  No play; does not get out of bed  Moribund; fatal processes progressing rapi[INVESTIGATOR_375]  
0  Unresponsive  Dead  
Source: http://asbmt.affiniscape.com/associations /[ZIP_CODE]/files/ResponseCrite riaAPPENDIXAFormA.pdf 
 
  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
 
Pharmacyclics LLC Proprietary and Confidential Page 90  Score 0 Score 1 Score 2 Score 3 
JOINTS AND FACIA □ No Symptoms □ Mild tightness of arms or 
legs, normal or mild 
decreased range of 
motion(ROM) AND not 
affecting ADL □ Tightness of arms or legs 
OR joint contractures, erythema thought due to 
fasciitis, moderate decrease 
ROM AND mild to moderate limitation of ADL □ Contractures WITH 
significant decrease of ROM AND significant limitation of 
ADL (unable to tie shoes, 
button shirts, dress self etc) 
□ Abnormality present but explained entirely by [CONTACT_105]-GVHD documented cause (specify):____________________________ 
 Score 0 Score 1 Score 2 Score 3 
EYES □ No symptoms □ Moderate dry eye 
symptoms not affecting ADL (requirement of lubricant eye 
drops ≤ 3 x per day) □ Moderate dry eye 
symptoms partially affecting 
ADL, (requiring eye drops > 
3 x per day or punctual 
plugs), WITHOUT new vision impairment due to 
KCS □ Severe dry eye symptoms 
significantly affecting, ADL 
(special eyeware to relieve 
pain) OR unable to work 
because of ocular symptoms OR loss of vision due to KCS 
□ Abnormality present but explained entirely by [CONTACT_105]-GVHD documented cause (specify):_____________________________ 
 Score 0 Score 1 Score 2 Score 3 
LUNGS □ No symptoms □ Mild symptoms (shortness 
of breath after climbing one flight of steps) □ Moderate symptoms 
(shortness of breath after walking on flat surface) □ Severe symptoms 
(shortness of breath at rest; requiring O
2) 
□ Abnormality present but explained entirely by [CONTACT_105]-GVHD documented cause (specify):____________________________ 
 
  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA Amendment 2 21 October 2015 
Final 
 
Pharmacyclics LLC Proprietary and Confidential Page 91 RANGE OF MOTION: 
 
□  Not done  
□  Not done  
□  Not done  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA-Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 92 Appendix G. Chronic GVHD  Activity Assessment − Patient Self Report 
FORM B  Today’s Date: ________________________ MR#/Name: ________________________  
 
CHRONIC GVHD ACTIVITY ASSESSMENT-PATIENT SELF REPORT 
 
Symptoms   
 
 
Not                                                                                                                       As Ba d As You  
Present                                                                                                                    Can Imagine  Please rate how severe the following 
symptoms have been in the last seven 
days. Please fill in the circle below 
from 0 (symptom has not been present) to 10 (the symptom was as 
bad as you can imagine it could be) 
for each item.  [ADDRESS_843572]?            
Your mouth dryness at its WORST?            
Your mouth sensitivity at its WORST?            
 Eyes What is your main complaint with regard to your eyes?  
 
Please rate how severe is th is eye symptom, between 0 
(not at all severe) and 10 (most severe): 0   1   2   3   4   5   6   7   8   9   10 
 Vulvovaginal Symptoms 
(females only) Do you have any burning, pa in or discomfort in the 
area of your vagina, vulva or labia? OR Do you have any discomfort  or pain with sexual 
intercourse?  
o Yes 
o No 
o Not applicable 
 
Patient Global Ratings:  
1. Overall, do you think that your chronic graft v ersus host disease is mild, moderate or severe?  
0= none  
1= mild  2=moderate  3=severe  
 
2. Please circle the number indicating ho w severe your chronic graft versus host disease symptoms are, where [ADDRESS_843573] severe cGVHD  
not at all                                                                                                                                                               severe symptoms  
                                                                                                                                                                                 possible  
 
3. Compared to a month ago, 
overall would you say that your cGVHD symptoms are:  
+3= Very much better  
+2= Moderately better  
+1=A little better  
0= About the same  -1=A little worse  
-2=Moderately worse  
-3=Very much worse  
Attach copi[INVESTIGATOR_1309]:  
 
Adults (persons 18 years or older):  
o Lee cGvHD Symptom Scale  
o Human Activity Profile  
o SF-[ADDRESS_843574]-BMT    
Children/Adolescents (persons 17 years or younger):  
o Lee cGVHD Symptom Scale (persons 8-12 years old may complete with help of the health care professional)  
o ASK - Activities Scale for Kids  
o CHRIs - Generic and Disease Specific Inventory  
Source: http://asbmt.affiniscape.com/associations /[ZIP_CODE]/files/ResponseCriteriaAPPENDIXBFormB.pdf
  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA-Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 93 Appendix H. Response Criteria for Part ial Response and Progression in cGVHD 
Proposed calculations for partial response in chronic GVHD  
 
Organ and Starting Score or Value  Partial Response Criterion*  
Skin (percent of body surface)    
> 50  e/s ≤ 0.5 and e > 0  
25 – 50  s – e ≥  25 and e > 0  
< 25  only CR; no PR possible  
Eye (mm Schirmer’s test)    
< 5 mm  e – s ≥ 5 mm and e < LLN  
5 – 10 mm  only CR; no PR possible  
Mouth (15-point Schubert scale)    
≥8  e/s ≤ 0.5 and e > 0  
4 – 7  s – e ≥ 4 and e > 0  
< 4  only CR; no PR possible  
Platelet count  e – s ≥ 100,000/uL and e < LLN  
Gastrointestinal (and other 0 – 3 scales)†    
3  e = 1 or 2  
2  e = 1  
1  only CR; no PR possible  
Liver function tests (ALT, alkaline phosphatase and 
bilirubin) and eosinophil count    
≥ 3x ULN  e/s ≤0.5 and e > ULN  
< [ADDRESS_843575]  only CR; no PR possible  
* s, starting score or value; e, ending score or value;  ULN, upper limit of normal; LLN, lower limit of normal 
† The proposed response criterion could be appropriate for shorter-term phase II studies. For longer-term pi[INVESTIGATOR_631949], a 1-point change might not be sufficient for PR. 
 Examples :
 
1. Skin: start score = 85, end score = 30; e/s = 30/85 = 0.35 = PR  
2. Skin: start score = 65, end score = 45; e/s = 45/65 = 0.75 = not PR  
3. Skin: start score = 45, end score = 15; s – e = 30 = PR  4. Skin: start score = 30, end score = 15; s – e = 15 = not PR  
 
 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA-Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 94 Appendix H. Response Criteria for Partial Re sponse and Progression in cGVHD (Cont'd) 
 
Proposed calculations for progression in chronic GVHD 
 
Organ and Starting Score or Value  Progression Criterion*  
Skin (percent of body surface)  e – s ≥  25  
Eye  s – e ≥ 5 mm  
Mouth (15-point Schubert scale)  e – s ≥ 3  
Platelet count  s – e ≥ 50,000/uL and e < LLN 
Gastrointestinal (and other 0 – 3 scales)  e – s ≥  1  
Liver (ALT, alkaline phosphatase and bilirubin), eosinophil count    
s ≥ 3x ULN  e – s ≥ [ADDRESS_843576]  
s < 3x ULN  e – s ≥  [ADDRESS_843577]  
Lungs (12-point Lung Function Scale)  e – s ≥ 3†  
**Score changes from 0 to 1 are not considered progression. 
 
*s, starting score or value; e, ending score or value; ULN, upper limit of normal  
† If the starting lung function score is ≥ 10, progression is defined as ≥ 5% decrease of FEV1 in two tests measured 
at least 2 weeks apart. This time interval was se lected because these syndromes can progress rapi[INVESTIGATOR_375]. 
http://asbmt.affiniscape.com/associations/[ZIP_CODE]/f iles/ResponseCriteriaAPPENDIXC_DCalculations.pdf 
 
  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA-Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 95 Appendix I. Guidelines for Chronic GVHD Ac tivity Assessment – Clinician (FORM A) 
Any measure that is normal and does not have cGV HD involvement at Day 1 = NE (not evaluable), 
remains NE unless criteria for PD is met. 
Any measure that changes but is not felt to be related to cGVHD should be marked as NE. Organs with 
more than one component will have each component evaluated, and then an organ score will be assigned. 
Overall cGVHD assessment: SD: no PR, no PD, no CR 
PR: if no PD and ≥1 PR 
PD: if ≥1 PD 
CR: all CR 
Measures Individual 
Response* Overall organ response 
Skin (percent of body surface) 
Body surface area of erythematous rash  NE: no cGVHD 
SD: no PR, no PD, no CR 
PR: if no PD and ≥1 PR 
PD: if ≥ 1 PD 
CR: all CR Skin Body surface area of moveable sclerosis   
Skin Body surface area of non-moveable sclerosis  
Eyes – Right eye  Schirmer Tear Test (mm wetting)  NE: no cGVHD 
SD: no PR, no PD, no CR PR: if no PD and ≥1 PR 
PD: if ≥ 1 PD 
CR: all CR Eyes – Left Eye  Schirmer Tear Test (mm wetting)  
Mouth  
Mucosal change  
(Scores range from 0-15)  NE: no cGVHD 
SD: no PR, no PD, no CR PR 
PD 
CR 
Blood Counts 
Platelet count and absolute eosinophil count   NE: no cGVHD 
SD: no PR, no PD, no CR 
PR: if no PD and ≥1 PR 
PD: if ≥ 1 PD 
CR: all CR 
Liver Function Tests 
ALT, total serum bilirubin and alkaline phosphatase  NE: no cGVHD 
SD: no PR, no PD, no CR 
PR: if no PD and ≥1 PR 
PD: if ≥ 1 PD 
CR: all CR 
GI – Upper 
  NE: no cGVHD 
SD: no PR, no PD, no CR 
PR: if no PD and ≥1 PR 
PD: if ≥ 1 PD 
CR: all CR GI – Esophageal 
  
GI – Lower   
Lung response  Pulmonary Function Tests with Diffusing Capacity, 
FEV1 and DLCO   NE: no cGVHD 
SD: no PD PD  No possible PR or CR 
Overall cGVHD Response  SD: no PR, no PD, no CR PR: if no PD and ≥1 PR 
PD: if ≥ 1 PD 
CR: all CR 
*See Appendix H  for individual response 
  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA-Amendment [ADDRESS_843578] of inhibitors can be found at 
the following website: http://medicine.iupui.edu/clinpharm/ddis/table.aspx. The general categorization into 
strong, moderate, and weak inhibitors according to the website is displayed below. Refer to Section 6.2.1  on 
instructions  fo
r concomitant use of CYP3A inhibitors and inducers with ibrutinib. 
Inhibitors of CYP3A Inducers of CYP3A 
Strong inhibitors:  Carbamazepi[INVESTIGATOR_631950]:  Rifampin  
aprepi[INVESTIGATOR_36079]. John’s Wort  
erythromycin Troglitazone  
diltiazem   
fluconazole  
grapefruit juice  
Seville orange juice  
verapamil  
Weak inhibitors:   
cimetidine  
All other inhibitors:   
amiodarone  
NOT azithromycin  
chloramphenicol  
boceprevir   
ciprofloxacin  
delaviridine   
diethyl-dithiocarbamate   
fluvoxamine   
gestodene  
imatinib  
mibefradil  
mifepristone  
norfloxacin  
norfluoxetine  
star fruit  
telaprevir  
troleandomycin  
voriconazole  
Source:  http://medicine.iupui.edu/clinpharm/ddis/table.aspx . 
 
  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1129-CA-Amendment 2 21 October 2015 
Final 
Pharmacyclics LLC Proprietary and Confidential Page 97 Appendix K. Child-Pugh Score 
Measure 1 point 2 points 3 points 
Total bilirubin, μmol/L (mg/dL) <34 (<2) 34-50 (2-3) >50 (>3) 
Serum albumin, g/L (g/dL) >35 (>3.5) 28-35 (2.8-3.5) <28 (<2.8) 
PT INR <1.7 1.71-2.30 >2.30 
Ascites None Mild Moderate to Severe 
Hepatic encephalopathy None Grade I-II (or suppressed 
with medication) Grade III-IV  
(or refractory) 
 
Points Class 
5-6 A 
7-9 B 
10-15 C 
 
Source:  
1. Child CG, Turcotte JG. “Surgery and portal hypertension”. In Child CG. The liver and portal hypertension. 
Philadelphia:Saunders. 1964. pp. 50-64.   
2. Pugh RN, Murray-Lyon IM, Dawson L, Pi[INVESTIGATOR_9051], Williams R . “Transection of the oesophagus for bleeding oesophageal varices”.  The British jour nal of surgery, 1973;60: 646-9. 